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It is established that the mildly learning disabled population has a three fold elevated 
risk for schizophrenia.  On the basis of findings from previous neuroimaging studies it 
has been proposed that in some individuals learning disability is a prepsychotic 
manifestation of schizophrenia.  On this background, a cohort was selected from a 
nonpsychotic adolescent population in special education by employing tools 
previously shown to identify those at elevated risk of schizophrenia from within a 
high risk population.  The risk of developing schizophrenia within this selected cohort 
was expected to be substantially greater than that for the learning disabled population 
as a whole.  This population was then assessed by clinical interview, 
neuropsychological assessment and MRI scanning.  Region of interest methodology 
was employed to ascertain amygdala volume in both the high risk and a matched 
control group.  Two primary areas of interest were addressed; comparison of 
amygdala volume between the two groups and investigation of the relationship 
between symptomatology and amygdala volume within the high risk population.  
While no significant difference was found between amygdala volume in the high risk 
and control groups, a significant negative correlation was seen between left amygdala 
volume and weight of negative symptoms within the high risk group (p=0.009).  This 
suggests that within this population reduced amygdala volume may be significant in 
the aetiology of negative-type symptoms and these symptoms may be present prior to 
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1.1 Why the amygdala is of interest in schizophrenia 
 
History of understanding of amygdala function 
  
 It has long been postulated that the amygdala may be a significant brain 
structure in the aetiology of schizophrenia.  This mooting of the amygdala was 
initially proposed on the basis of theoretical considerations, but as evidence has 
accumulated this has been supported by experimental data.  
 When the evolution of understanding of amygdala function is considered, it is 
easy to see why it has drawn interest from researchers in schizophrenia.  The 
experience of fear is a prominent feature of this condition,1 and behavioural change is 
often associated; both of these phenomena have long been linked with amygdala 
function. In relation to the latter, the early work of Kluver and Bucy revealed that 
amygdala damage resulted in dramatic behavioural change.2  Additionally, 
amygdalectomised monkeys appeared to no longer experience fear,3 and as data has 
accumulated the importance of the amygdala in the experience of this emotion has 
been further supported.  Michael Davis has reviewed the role of the amygdala in 
conditioned fear, anxiety and attention.4  He summarises data supporting the idea that 
the amygdala, together with its many projections, may represent a central fear system 
involved in both the expression and acquisition of conditioned and unconditioned 
fear.  This data includes findings from various animal species, acquired using 
disparate techniques. Some examples of this laboratory acquired data are that 
electrical stimulation and lesions of the amygdala respectively mimic or block natural 
and conditioned fear; local infusions of drugs such as flumazenil and morphine into 
the amygdala can have, respectively, anxiogenic and anxiolytic effects; and that 
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amygdala NMDA receptors are important in the acquisition of conditioned fear.4  
Additionally, fear and anxiety often precede temporal lobe epileptic seizures, which 
are usually associated with abnormal electrical activity of the amygdala.  Given the 
centrality of fear to the experience of schizophrenic illness, on the basis of this data 
alone the potential significance of this structure is intriguing.    
 As understanding of amygdala function has expanded, its proposed role in 
attaching salience to stimuli and its importance in emotional memory have been 
intensively investigated.  It is certainly a structure well placed for such a role.  Rat 
studies have shown that it receives highly processed sensory information, primarily 
through its lateral and basolateral nuclei.4  These nuclei then project to the central 
nucleus, which in turn projects to hypothalamic and brainstem areas that directly 
mediate specific signs of fear and anxiety.  The central nucleus of the amygdala also 
has the potential for widespread indirect effects on the cortex via other projections.4   
In animal studies electrical stimulation of the amygdala appears to result in increased 
attention.5  
 The importance of the amygdala in conditioned fear is suggested by data such 
as that reporting that human subjects with amygdala lesions have deficits in classical 
fear conditioning using galvanic skin response as a measure.6  Animal studies have 
linked specific lesions with specific deficits, with central nucleus lesions blocking the 
normal cardiovascular changes that develop during classical fear conditioning.  For 
example, in rabbits, a cue paired with shock leads to bradycardia that can be blocked 
by either chemical or mechanical lesions of this region.6,7,8  Other studies have shown 
that both NMDA-dependant and NMDA-independent long term potentiation can 
occur in both amygdala brain slices and in vivo4 and that local infusion of an NMDA 
antagonist can prevent the acquisition of fear potentiated startle.9  As well as aversive, 
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the amygdala appears also to be involved in appetitive associations; examples include 
association of visual cues with drug taking.10  Overall however data suggests that the 
amygdala, like the hippocampal formation, plays a temporally limited role in memory 
processing, and is not the permanent memory storage site.4  For avoidance-type 
responses as well as other forms of memory, it seems likely that the amygdala 
promotes memory storage in various non-amygdalar brain circuits, with this 
promotion dependant on the emotional significance of the events to be recorded.11 
 As described above, it has been shown that the amygdala is important in a 
variety of motivated behaviours in various species.  It has been proposed that in 
humans however the amygdala has specialised to be particularly important in 
processing information relevant to the social domain, and is disproportionately 
important for social cognition and motivation of social behaviour.12  One aspect of 
this is making judgements about the internal states of others based on expressed 
emotions.  The role of the amygdala in the recognition of emotions of negative 
valence important to social interaction has long been recognised.  For example, 
humans with bilateral amygdala damage have particular impairments in making 
judgements about such emotions, often with particular difficulties in recognition of 
fear.12  While more recent studies have shown that the effect of amygdala damage on 
emotion recognition does show individual variation, with emotions other than fear 
being affected in some, the data does support it having a particular role in emotions of 
negative valence.  Additional support for this role comes from functional studies, in 
normal individuals, which have shown amygdala activation to be particularly 
pronounced when looking at fearful faces.13,14  The importance of the amygdala in the 
human social domain may however be broader still, going beyond simple emotion 
recognition, and extending to social judgements and theory of mind abilities.  
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The role of the amygdala in social judgements was first suggested by studies 
in non-human primates, which demonstrated impaired social behaviour following 
amygdala damage.15  More recent studies suggest a role for the amygdala in so-called 
theory of mind abilities.  This term encompasses the collection of abilities whereby 
we attribute internal mental states, intentions, desires, and emotions to other people.  
There is substantial data to support the idea that the amygdala plays an important role 
in it.  For example, studies have shown that subjects with bilateral amygdala damage 
were specifically impaired in their ability to judge the untrustworthiness and 
inapproachability of people in photographs.16  A further case report describes marked 
impairment of theory of mind in the context of preserved executive function in an 
individual with unilateral, left sided amygdala damage.17  Thus, they say, it seems 
highly likely that there is dissociation between these two spheres of ability.  
Additionally, functional imaging studies in normal individuals have shown increased 
amygdala activation when looking at untrustworthy rather than trustworthy 
photographs of people.  A further study suggests an even broader role for the 
amygdala in making more general social attributions; individuals with amygdala 
damage were unable to make these based on the motion of visual stimuli, while 
unimpaired individuals found it difficult not to.12  
Two other groups of researchers have investigated the role of the amygdala in 
social cognition through very different means.  Intriguingly, Barton and Aggleton 
reported that there was a correlation between the volume of the basolateral amygdala, 
the size of the neocortex, and the size and complexity of social groups in 83 species of 
primates and insectivores.18  A very different study, in humans, investigated if people 
with amygdala damage were particularly impaired in recognising social emotions 
compared to more basic emotions; these are emotions such as jealousy, pride or 
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embarrassment, which necessarily require a social context.  This was indeed found to 
be the case.19   
If it is accepted that the amygdala is indeed important in motivated behaviour, 
how may it fulfil this role?  One proposal is that it associates a representation of a 
stimulus with a representation of the emotional and social contingencies.  This can 
thus result in modulation of behaviour.  While this provides a hypothesis for the role 
of the amygdala in motivational behaviour however, it does not explain why it would 
have a disproportionate role in processing social stimuli and be central to social 
cognition. This is important, as the weight of evidence above does indeed suggest that 
the human amygdala has a disproportionate role in processing those stimuli (and 
possibly especially visual stimuli), that have an explicitly social significance.12  
Unfortunately this question is largely unanswered.  
 
 
Relevance of understanding of amygdala function to schizophrenia 
  
 If it is the case that the amygdala has importance in attaching emotional  
salience to stimuli and particularly in processing social stimuli its potential 
significance in schizophrenia is clear.  Studies have shown that patients with this 
condition do appear to show impairment in their ability to identify and accurately 
interpret emotions from sources such as facial expressions.  They also exhibit deficits 
in emotion processing, emotional experience and behaviour with an apparent 
emphasis on the decoding and encoding of negative emotions.20,21  Neutral stimuli are 
frequently imbued with great emotional significance which is often fearful, the 
emotion most closely associated with the amygdala.  Impairments in emotion 
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perception and processing have been closely associated with the inability of many 
patients with schizophrenia to interpret various social cues appropriately and in proper 
context with respect to a given social situation.  This can contribute to the formation 
of social cognitive biases, such as to judge others more negatively, as well as to 
conclude that others hold strong unfavourable impressions of them.22  Interestingly, 
though patients free of positive symptoms show better performance in their ability to 
recognize and make social judgements from facial expressions, even those largely free 
of positive symptoms show deficits in social cognition.23  Functional imaging studies 
have also shown abnormalities of emotional processing in individuals with 
schizophrenia.  One such study involved functional imaging of a group of individuals 
with schizophrenia during an emotion recognition task.  It showed that relative to 
healthy comparison participants, individuals with schizophrenia were not only less 
accurate in identifying emotions, but also displayed no amygdalar activation to fearful 
expressions.24 
            Given the deficits in emotion perception and processing described above, 
various hypotheses have been proposed to explain how amygdala dysfunction could 
be responsible for them.  It has been suggested that patients with schizophrenia fail to 
activate their amygdala in response to sad, aversive or threatening stimuli, leading to 
failure to process fearful or threatening stimuli.25  This could contribute to difficulty 
in recognition of some emotions.  Conversely, neutral stimuli result in amygdala 
activation to a stronger extent than in normal subjects, leading to the aberrant 
assignment of salience to otherwise insignificant stimuli.25  By the latter theory it can 
be seen how psychotic symptoms such as delusions of reference, and even primary 
delusions could occur.  Indeed, there is some support for the above theories from 
functional imaging studies; Taylor et al found that activity in the left amygdala 
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correlated with positive symptoms (higher levels of symptoms associated with higher 
levels of activity), suggesting that amygdala activation may indeed be involved with 
positive symptom generation.26 
 While there has been much focus on the amygdala being important in the 
aetiology of positive symptoms, less attention has been paid to its potential role in 
negative symptoms.  It is often argued that frontal lobe impairments are most likely 
the cause of these symptoms, as features such as psychomotor retardation, avolition 
and attentional impairment suggest deficits in this brain region.  Further weight is 
given to this theory by findings such as smaller prefrontal white matter volumes being 
associated with severity of negative symptoms,24 and patients with predominantly 
negative symptoms having lower levels of glucose metabolism in the prefrontal cortex 
compared to comparison subjects.27  Given the weight of evidence for the importance 
of the amygdala in motivational behaviour and its role in processing social stimuli 
however, an argument can also be made for the potential involvement of the amygdala 
in this constellation of symptoms. Additionally, these brain regions are likely 
intimately related; in Brothers seminal article proposing a neural system of social 
cognition for example, this system was composed of the amygdala as well as the 
superior temporal sulcus and orbitofrontal cortex.28  On considering specific negative 
symptoms, an impairment in the drive for social interaction could clearly be 
significant in apathy and anhedonia, and decrease in emotional expression has 
potential links to defects in emotional recognition.  Interestingly, and contrary to some 
findings (discussed below), if the amygdala was involved in such symptoms we might 
expect to see greater abnormalities in the right rather than left amygdala; this may be 
expected as there is some suggestion that the right side of the brain may be more 
involved in the identification and expression of emotion.27 
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On attempting to relate what is known about amygdala function to the social 
impairment that is such a significant consequence of negative symptoms, there is 
some evidence of an association.  There is evidence, for example, that social 
dysfunction is predicted to a larger degree by impairments in facial affect recognition 
than by impairments in non-social cognitive functions such as memory, attention and 
executive functioning.24  It seems logical to expect that apathy and avolition would be 
compounded by repeated ill judged attempts at social interaction which if based on an 
incorrect assessment of social information lead to further rejection and ultimately 
withdrawal.   
Though amygdala involvement in negative symptoms is theoretically 
attractive, data supporting this is sparse.  Potkin et al did find that only subjects with 
predominantly positive symptoms had increased glucose metabolism in the extended 
amygdala, but both the predominantly negative and positive symptom groups had 













1.2 Literature review of amygdala imaging studies 
 
Introduction to imaging summary 
 
 Since Johnstone et als finding of increased ventricular size in people with 
schizophrenia,29 it has been clear that there are structural abnormalities in the brains 
of this patient group.  The most immediate challenge was to establish which brain 
structures were reduced to account for the increase in ventricular size.  Unfortunately, 
initial studies investigating specific brain regions were hampered by the limitations 
inherent in the technology of the time.  Since this seminal research however, imaging 
techniques have become more sensitive and brain structures easier to delineate and 
measure.  This development of technology has been accompanied by continued 
interest in identifying structural abnormalities in brains of people with schizophrenia, 
with a wide variety of brain regions being targeted for investigation.  Amongst these 
studies there has been particular interest in medial temporal lobe structures, with the 
hippocampus and amygdala receiving considerable attention.  The reason for this 
interest is twofold: Firstly reduction in medial temporal lobe volume has been one of 
the more consistent findings in imaging studies.30  Secondly, as described above, the 
overlap between the psychopathology of schizophrenia and what we know of the 
functions of these brain structures make them prime candidates for involvement in the 
disease process. 
 The accumulated data on brain imaging in schizophrenia is vast and disparate. 
Given that this report concerns the amygdala, I will limit this review to data 
concerning this structure. Until recent years imaging techniques were not of sufficient 
sensitivity to enable separate measurement of the amygdala and hippocampus; for this 
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reason studies focused on measurement of the amygdala-hippocampal complex 
(AHC).  More recent studies, employing improved technology, have managed to 
differentiate the two structures.  For reasons of completeness I will include the earlier 
studies which measured the amygdala and hippocampus together in this discussion.  I 
will also, at times, refer to hippocampal measurements.   
   In vivo study of medial temporal lobe structures is a relatively recent 
endeavour.  This is largely because such studies were impossible before the 
availability of MRI, which made possible the accurate separation of grey and white 
matter.  Since the advent of this technology however, techniques employed in the 
measurement of these structure have progressively increased in sophistication.  While 
initial studies involved hand tracing for example, over time this was superseded by 
semi-automated region of interest methodology.  Indeed, though laborious, this 
remains the gold standard.31  In recent years techniques have progressed further still, 
and there has been increasing interest in fully automated processes of regional 
measurement.  One of the most prominent of the latter processes is voxel based 
morphometry (VBM).  The variety of techniques all provide useful data and so, 
although this study involves region of interest methodology, these other techniques 
will also be included in the review.  
 On reviewing studies concerning amygdala volumetry, it is rapidly apparent 
that significant differences in methodology can exist between studies.  This has 
potentially significant implications.  One of the more important of these variables is 
differences in anatomical delineation, a point which will be expanded on later.  A 
further issue is that in some studies whole brain volume is controlled for, while in 
others it is not.  This is also potentially important.  Though individual studies have 
failed to find a significant difference in brain volume between people with 
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schizophrenia and controls,32 when studies are combined a reduction is seen.33,34  A 
volume reduction of about 3% has been suggested, mainly attributable to loss of grey 
matter.33  Whole brain volume reductions are particularly equivocal in first episode 
studies,35,36 but it must still be born in mind that if studies have not controlled for 
whole brain volume, then any volume reductions which are seen could be negated by 
this approach.  The methods employed in controlling for whole brain volume in 
imaging studies include either quoting structure volumes as a proportion of whole 




Review of studies investigating amygdala volume in schizophrenia   
 
 
1.2.1 Findings in studies of chronic schizophrenia 
 
 It is well recognised that symptom development in schizophrenia is not static, 
and indeed that impairment associated with the condition tends to accrue over time. 
Given this, distinct populations of individuals have been investigated; patients with 
chronic schizophrenia, first episode patients and those at high risk of the condition. 
Additionally there have also been studies of first degree relatives of those with 
schizophrenia; individuals who obviously share genetic factors with effected 
individuals, but lack disease-specific differences.  If neuroanatomical abnormalities 
are associated with the condition however, then if present in any group, they would be 
expected to be most marked in those with chronic schizophrenia.  Unsurprisingly, it 
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was indeed in this group that ventricular enlargement was first observed.  As imaging 
sensitivities improved, so amygdala size in those with schizophrenia could be 
investigated in comparison to controls.  In a 1998 systematic review by Lawrie and 
Abukmeil they discuss six studies comparing volumes of the amygdala in those with 
schizophrenia with controls.33  They include studies investigating both chronic and 
first episode cases published before June 1996.  The nature of the studies meant a 
median evaluation of amygdala volume reduction could only be made for men, but 
this suggested a large and bilateral reduction of about 10%.  The methodology did not 
control for whole brain volume.  They felt the durability of this finding was supported 
by the fact that studies covering only the anterior part of the temporal lobe or AHC 
also reported large size reductions. 
 Since the review described above further studies have been published 
investigating the association between schizophrenia and amygdala size.  Wright et al 
undertook a meta-analysis of structural imaging studies in schizophrenia involving 
volumetric brain MRI measurements made by region of interest technique published 
up to 1998, which again included chronic and first episode cases.34  This review was 
based on seven studies that measured the amygdala as a distinct structure, volume not 
being adjusted for whole brain volume.  It did show however that relative to the 
global reduction in cerebral volume, amygdala volumes were relatively small being 
94% on the left and right compared to controls.  A more recent review by Shenton et 
al includes studies published up to August 2000.  Though meta-analysis is not 
attempted, the number of studies discussed is increased and they report that 74% of 
studies have positive findings compared to 26% negative.  They discuss that evidence 
supports a volume reduction in the AHC compared to controls, though question 
whether these findings are specific to schizophrenia.38  They also report that a 
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substantial number of studies demonstrate left-lateralized findings for AHC volume 
reductions, particularly in male patients. 
 Single studies of note include that of Gur et al in 2000, a relatively large study 
including 100 individuals with a mixture of first episode and chronic schizophrenia 
and 110 healthy controls.39  This study was included in the review of Shenton et al 
discussed above.  They reported decreased amygdala volume in men with 
schizophrenia (by 8%), but increased volume in women (by 10.5%).  This 
dissociation between the sexes seems an isolated finding.  A 2005 study by Suzuki et 
al employing ROI methodology to compare amygdala volume in people with 
schizophrenia, schizotypal disorder and controls found both right and left amygdala 
volume to be significantly reduced in schizophrenic subjects compared to controls.40     
   
 
1.2.2 Review of findings in first episode studies 
 
 Early reviews commenting on amygdala size in schizophrenia had tended to 
include both chronic and first episode patients together.  As studies accumulated 
however separate analysis of data relating to the two groups became possible.  By the 
time of Shenton et als review, above, data are listed separately for a number of such 
studies already undertaken.  Data continued to accumulate however, and two meta-
analyses of cross-sectional studies investigating brain abnormalities in first episode 
patients were published in 2006.  Vita et als review looked at right and left amygdala 
separately.  Their quantitative meta-analysis, involving a total of 115 patients and 88 
controls, though finding a trend towards smaller amygdala in cases, greater in left 
than right, did not reach significance.41  The methodology did not control for whole 
 22
brain volume.  Interestingly they did find a significantly reduced hippocampal volume 
(left and right) leading to speculation that this structure may be affected earlier in the 
course of schizophrenia.  The other recent meta-analysis, including several additional 
studies, was undertaken by Steen et al.42  Unfortunately this meta-analysis did not 
include amygdala size, though it did find a statistically significant reduction in both 
right and left hippocampal volume of 8%. 
 For reasons that are not clear, one particular potentially interesting first 
episode study was not included in the meta-analysis of Vita et al.  This is a study 
undertaken by Joyal et al, in which amygdala volume was determined in a group of 
medcation-naive patients with schizophrenia.  As exposure to neuroleptics can so 
often be a potential confounding factor in studies of schizophrenia, though a small 
study (18 patients with schizophrenia and 22 controls), it is still worthy of discussion. 
It found, after controlling for intracranial area, gender, age and handedness, that 




1.2.3 VBM studies in established schizophrenia 
 
 In addition to region of interest investigations, over recent years automated 
techniques of brain region measurement have also been developed.  Prominent among 
these is the technique known as voxel based morphometry (VBM).  As well as being 
less laborious, VBM also has the potential advantage of reducing any bias involved 
with user-dependant methods.  In addition this technique looks at changes in every 
voxel in the brain, meaning that the region investigated is not constrained by prior 
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hypothesis.  In their 2005 review of VBM studies, Honea et al report that volume 
deficits in the left amygdala are found in the majority of studies reviewed.44  This 
statement was made on a mixture of first episode and chronic schizophrenia patients.  
A notable single study included in this review was that that of Hulshoff Pol et al.  
They compared 159 patients to 158 healthy control subjects matched on age, sex, 
handedness and parental education.  A significant reduction in grey matter density 
was reported for the left amygdala in the schizophrenia group, in addition to a number 
of other specific brain regions.  The decreased density in the amygdala was more 
pronounced in older patients with schizophrenia.  It was thus suggested that illness 
duration may be associated with greater amygdala volume reduction.45  It must of 
course be acknowledged however that this study is potentially subject to selection 
bias, the older subjects having a more severe manifestation of the illness and this 
giving rise to the observed differences.   
 It is of note on reviewing VBM studies that it can be difficult with this 
technique to delineate the amygdala as a distinct structure, rather than brain region.  It 
is also the case that it can be very difficult to detrend brain size effects from local 
measures, and though compensatory mechanisms can be employed, it is recognised 
that brain size can confound with this technique.46  
 
 
1.2.4 Longitudinal studies 
 
The above data suggest that changes in the brains of those with first episode 
schizophrenia may be less marked than in those in the chronic stage of the illness.  If 
this was the case, it would suggest that there may be progressive brain changes over 
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time.  Evidence for this would clearly be stronger however if changes were shown to 
occur in a cohort with schizophrenia followed up over time, but not in a control 
group. Unfortunately however there are numerous practical difficulties in conducting 
studies such as these.  Most obvious is that of subject retention.  This is made even 
more problematic by the fact that brain volume loss over a year may be close to the 
limit of detection by MRI, necessitating lengthy studies.42  Actually being able to 
undertake comparable scans however can be an even greater problem, a concept 
known as machine drift.42  MRI machines are often not comparable even if the same 
model, and obviously in longitudinal studies by the time of the second scan the 
original machine may be obsolete.  A different machine at the second timepoint can 
thus introduce systematic bias.  Even if he same machine is used, positioning for the 
second scan may be different and produce distortion. 
Despite the practical difficulties detailed above, longitudinal studies have been 
carried out from the early 1990s.  One such MRI study by DeLisi and colleagues 
achieved follow up of 27 first-episode patients and 10 controls over ten years.  While 
progressive ventricular enlargement of cases was shown, progressively decreasing 
volume of the AHC was not.47  As well as the problem of scanner comparability over 
time, this is an early study with older equipment and thick slices; a relatively large 
interslice gap of 2mm was employed.  This reduces sensitivity in finding small 
differences still further.  Since this early study numerous other longitudinal studies 
have been undertaken; equipment employed has been more sensitive, but follow up 
periods often shorter.  These longitudinal studies were summarised by Pantelis et al in 
2005.48  Findings from these other studies have been inconsistent and at times 
surprising. Gur et al for example, in their study comparing first episode, established 
schizophrenia cases and controls found that while temporal lobe volume reduction 
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over time was greater in first episode than established cases, it was greatest of all in 
controls.49   
Only some of the studies reviewed by Pantelis et al specifically measure the 
AHC, and fewer still separately measure the amygdala.  Among those that do the 
former, Kasai et als study of thirteen first episode subjects followed up over an 
average of 1.43 years did not demonstrate a reduction in size of the AHC.50  James et 
als study was in an adolescent onset, not adult group, but did separate hippocampus 
from amygdala; while the average size of the left amygdale of the 16 in the study 
group was 12% smaller in males and 7% smaller in females compared to controls, 
further reductions were not demonstrated in the average 2.7 years follow-up period.51  
A literature search did reveal one more recent longitudinal volumetric study, 
not included in Pantelis et als review, in which attempts were made to measure the 
amygdala as a separate structure.  In this study, by Whitworth et al, 21 first episode 
and 17 multiple episode schizophrenia patients and 20 healthy controls were followed 
up for between two to four years.52  They thought accurate separation of the amygdala 
and hippocampus was not possible and so measured it as a single structure which was 
then divided into an anterior (amygdalar) and posterior (hippocampal) portion.  
Adjustments were made for whole brain volume.  Though there was a non-significant 
trend for smaller amygdala in patients compared to controls at both time points, there 
was no evidence for reduction in amygdala size in either patient group over time.   
 Overall these data suggest that if amygdala volume reductions do occur once 
schizophrenia has become clinically manifest, then they are small.  They do however 
add to the weight of data suggesting that at the point of first episode of psychosis the 
amygdalas of those with schizophrenia are smaller than those of controls. 
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1.2.5 High risk studies 
 
 As discussed above, there is little evidence for progressive reduction in 
amygdala size once schizophrenia has been diagnosed.  Even if this evidence was 
present however, with so many confounding factors such as exposure to medication 
and lifestyle, this would not necessarily mean that these changes are due to 
schizophrenia itself.  What would be more convincing in illustrating that any 
reductions in amygdala size were due to the process of the illness would be if brain 
changes were shown to correlate with the development of symptoms before 
medication is commenced.  Additionally, it would be of significant potential utility if 
it could be demonstrated that the brains of those who are destined to develop 
schizophrenia are different from those who are not, even before the disease has 
become manifest.  Investigation of this possibility would require the identification and 
imaging of subjects prior to the development of psychotic symptoms and follow up 
with repeated investigation during the time they do or do not develop schizophrenia. 
The need for such studies has long been recognised, but they are notoriously difficult 
to conduct.  These difficulties are similar to those described for all longitudinal 
studies.  Additionally however, as not all subjects under investigation will develop 
schizophrenia, to achieve adequate numbers who do cohorts must be large.  This 
magnifies difficulties such as subject retention and identification of appropriate 
controls.  Various approaches have been adopted by different research groups to 
circumvent these difficulties; I will focus on the findings from two of the most high 
profile of these groups, the Edinburgh and Melbourne groups, but also mention other 
relevant findings.  
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 The Melbourne group used a close in strategy to identify those symptomatic, 
clinically compromised, and help-seeking individuals at imminent risk of developing 
a florid psychosis, but not yet actually psychotic.  They expected 30-40% of this ultra-
high risk (UHR) group to make the transition to florid psychosis.  Their biggest study 
published to date consisted of 135 patients identified as UHR of whom 39 developed 
psychosis (UHR-P) and 96 did not (UHR-NP).53  The characteristics of these groups 
were compared to 162 first-episode patients (a mixture of schizophrenia, 
schizoaffective, affective and other psychosis), 89 chronic schizophrenics and 87 
normal controls, with measurement of amygdala volume (by ROI methodology) being 
among those criteria investigated.  While left hippocampi were of normal size in UHR 
subjects, and reduced in schizophrenic subjects (both first episode and chronic), this 
study found increased amygdala size in affective psychosis (a finding previously 
reported),54 or psychosis not otherwise specified, but normal amygdala size in 
subjects with schizophrenia and UHR subjects.  Though longitudinal results from this 
large cohort have not been published, there have been reports from a smaller group of 
UHR individuals who did develop psychosis.55  In this study 75 UHR subjects where 
identified of whom 23 had developed psychosis after at least 12 months.  Ten who 
had developed psychosis and 11 who had not were rescanned after this time period 
and the scans compared by VBM.  Though the amygdala is not specifically mentioned 
they did find that there were smaller volumes of grey matter in the temporal lobes at 
the time of first scan in those of the UHR group who went on to develop psychosis 
compared to those who did not, and that further reductions occurred in this group 
between the two timepoints.  Longitudinal findings from the larger cohort are awaited. 
The Edinburgh group recruited at an earlier stage still; before those who could 
be destined to develop psychosis had made any attempts to seek help.  Subjects were 
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defined as being high risk by virtue of having two affected relatives.  They were 
identified in adolescence before clear manifestation of schizophrenia, assessed at this 
point and followed up for ten years.  This was achieved, in brief, by identifying from 
among the population of individuals with schizophrenia, those who had both a family 
history of the condition and adolescent relatives.  Diagnosis of schizophrenia was 
verified, relatives of the individuals with schizophrenia approached, and high-risk 
subjects aged 16-25 who agreed to participate given a detailed clinical, 
neuropsychological and brain imaging assessment.  These assessments were then 
repeated after approximately 2 years in consenting participants.  Two control groups, 
one consisting of individuals without a family history of schizophrenia and one of 
first-episode schizophrenics were also recruited.  These groups were subject to the 
same investigations as described above. 
  
 Results from the Edinburgh High Risk Study (EHRS) have now been 
published.  The findings at the start of the study are themselves interesting.  At 
baseline, ROI analysis found that the mean volumes of the left and right AHCs in high 
risk subjects were significantly smaller than those in controls (about 4%), but larger 
than those in first-episode schizophrenics (by about 4%).56  Whole brain volume, 
together with other factors such as sex and age were controlled for.  This finding 
suggests that abnormalities in this region may indeed pre-date the onset of psychosis.  
On both sides this result was highly significant, (<0.01), but significance was greater 
on the left.  On analysis of scans with automated VBM overall findings were similar 
to those by ROI methodology.  It is the case however that though amygdala volume 
reductions were seen on comparing first-episode to high risk subjects by VBM, these 
were not present comparing high risk and controls.57  Though this is surprising, it is 
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recognised that some differences can exist in findings from the two methodologies, 
and ROI techniques are regarded as the gold standard.31   
There is also evidence of brain structural changes as psychotic symptoms 
develop over time.  In their 2002 paper Lawrie et al discuss their finding that within a 
high risk group of 66 patients, the 19 with transient or isolated psychotic symptoms 
(12 of whom had these at the point of first assessment, of importance these symptoms 
were not of sufficient severity to justify a diagnosis of schizophrenia) display a 
statistically significant greater volume reduction in the right temporal lobe when 
compared to those without psychotic symptoms over approximately two years.58  A 
reduction was also seen in the left temporal lobe, though this did not reach statistical 
significance.  Amygdala-hippocampal complex measurements were also repeated by 
ROI methods at this timepoint; though no significant volume reduction was seen in 
this structure, it is suggested that the measurement error inherent in this method may 
have obscured a reduction which did occur.56  The fact that only 66 of the high risk 
subjects could be included in this analysis is worthy of mention and underlines one of 
the difficulties with longitudinal studies raised above.  In this study the scanning 
machine was changed halfway through the study and so only 66 high risk subjects, 
those recruited earliest into the study, had both initial and follow up scans on the same 
machine.  As a second scan with a different machine could introduce systematic bias, 
only those subjects with scans on the same machine, with current methodologies at 
least, are appropriate for comparison.            
As mentioned above, in addition to ROI analysis the EHRS scans were also 
analysed with VBM.  This was used to both investigate baseline differences between 
the three groups and changes within the groups over the two years between the first 
and second scans.  Particular attention was paid to the amygdala-hippocampal 
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complex.  By the end of the EHRS 21 high risk subjects had developed schizophrenia, 
often some years after the second scan.60  Of these 21, 8 had both the initial and 
follow up scans on the same machine; this was again due to the scanner being 
changed midway through the study.  By VBM methodology, reduction over time in a 
variety of left temporal lobe structures (rather than being more pronounced in the 
right temporal lobe, as in the ROI study) was seen in high risk subjects with transient 
or isolated psychotic symptoms.  Additionally, this group showed reductions in the 
right amygdala, but these latter changes were not sustained when significant changes 
in those high risk subjects without psychotic symptoms were excluded.  In those eight 
subjects who had developed schizophrenia by 2003 however, grey matter density 
reductions were seen in the left temporal lobe in baseline scans when compared to 
controls; over time further volume reductions were seen in the left uncus, statistically 
significant after making an amygdalo-hippocampal volume correction designed to 
encompass the whole amygdale and hippocampus.60  
 
Relevant findings in other high risk populations 
 Further interesting findings in a high risk population have been published from 
a population in Pittsburgh.61  This study investigated brain volumes in unaffected, 
young offspring of schizophrenia patients, individuals at high risk of developing 
schizophrenia.  This group measured amygdala and hippocampus together and 
reported reduced volumes of the left anterior and posterior AHC, after adjusting for 
intracranial volume.  The anterior AHC can be considered to correspond roughly to 
the amygdala. The authors suggest these abnormalities to be of neurodevelopmental 
origin. Of note, reductions in volume of the dorsolateral pre-frontal cortex (DLPFC) 
were not seen in this population, leading to speculation that these may occur later than 
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AHC changes, a possibility they related to the DLPFC being the last part of the brain 
to mature.  
 
 
1.2.6 Functional imaging studies investigating the role of the amygdala in 
schizophrenia 
 
 Functional imaging studies have also been employed to investigate 
abnormalities in the brains of people with schizophrenia.  Findings of abnormalities of 
amygdala activation in patients with schizophrenia are discussed by Aleman and 
Kahn in their 2005 review.25  Studies reported show lack of amygdala activation 
during negative affect62 and lack of amygdala activation in response to fearful 
expressions.63  A study by Taylor et al demonstrated less activation of the right 
amygdala in subjects with schizophrenia compared to controls, together with 
increased activity in the left amygdala of patients correlating with higher levels of 
positive symptoms.26  From the latter data it is discussed that reduced amygdala 
activity may underlie deficits in emotion recognition, while activation may be 
involved in positive symptoms.  Overall however the conclusions of this review are 
that the most consistent picture to emerge from functional neuroimaging studies in 
schizophrenia is of reduced activation of the amygdala in response to emotional 
stimuli compared to neutral stimuli.  It may well be that this is coupled to stronger 
activation of the amygdala in response to neutral stimuli than is the case in controls; 
this, of course, would fit with a model of aberrant assignment of salience.   
 To identify studies addressing abnormalities of amygdala activation in 
schizophrenia published since Aleman and Kahns review a literature search was 
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undertaken.  Search terms were schizophrenia combined using the AND operator 
with imaging and amygdala.  The search was run on EMBASE, PsychINFO and 
Medline.  Relevant papers are summarised in Table 1.1 below. 
 As can be seen from Table 1.1, findings are at times somewhat contradictory 
and remain inconclusive; this is likely at least partially due to the heterogeneity of the 
groups investigated.  For this reason particularly the paper of Fahim et al is 
interesting, as it does attempt to subdivide the schizophrenia group.64  Also of note is 
the Holt et al study, which reported elevated activation of the right amygdala during 
neutral as well as fearful face observations;67 this is at odds with the findings 
summarised by Aleman and Kahn.25  This discrepancy may of course be due to group, 
medication and subtle task differences. If these possibilities are left aside however, 
this finding does contradict the theory that a lesion of the amygdala is associated with 
a reduction in neural response to emotional stimuli and consequent inability to process 
other peoples emotions.  Instead findings could be interpreted to suggest a more 
general dysregulation of the amygdalar response to social stimuli, in which interplay 
with regions such as the anterior prefrontal cortex is likely significant.  Indeed, in-
keeping with this, there is substantial evidence demonstrating the importance of 











Comparison groups Relevant findings Possible significance of 
findings 
Fahim et al64 fMRI comparison of 
subjects with 
schizophrenia with (13) 





brain activity in the 
lingual gyrus in group 
without flat affect only  
Speculate that in flat affect 
amygdala malfunction renders 
amygdala unable to correctly 
evaluate the emotional meaning of 
pictures presented and hence link 
to parts of brain implicated in 
physiological and experiential 
dimensions of emotion. 
Laurens et al65 fMRI comparison of 
subjects with 
schizophrenia (28) and 







during novel stimulus 





Suggest that patients less 
effectively reorient processing 
resources away from the ongoing 
task, and experience increased 
distraction by novel stimuli. 
Believe this may indicate 
decreased efficiency of information 
processing. 
Das et al66 fMRI comparison of 
subjects with 
schizophrenia (14) with 
controls (14) on 





amygdala activity in 
response to fearful 
facial expression and 
abnormal patterns of 
connectivity with the 
brainstem, visual 
cortex and regions of 
the MPFC 
Indicate that sensory processing of 
potential threat is disrupted in 
schizophrenia. Breakdown of 
connectivity may limit the degree 
to which regions such as the 
amygdala are effectively engaged 
during fear processing. May 
contribute to a cycle of 
misattribution about incoming 
signals of potential threat in 
schizophrenia.   
Holt et al67 fMRI comparison of 
subjects with 
schizophrenia (15) and 
control subjects (16) 
viewing faces 
displaying fearful, 
happy and neutral 




activation during the 
initial presentation of 
fearful and neutral 
facial expressions, and 
greater hippocampal 
activation on viewing 
all three.  
Elevated MTL responses to neutral 
facial expressions compatible with 
a bias towards assigning emotional 
meaning to neutral information 
(aberrant assignment of emotional 
salience).   
Sanjuan et al68 fMRI comparison of 
subjects with 
schizophrenia (11) and 
control subjects (10) 
exposed to neutral and 
emotional words   
Enhanced activity of 
frontal lobe, temporal 
lobe, insula, cingulate 
and amygdala (mainly 
right side) in subjects 
hearing emotional 
words. No clear 
activation in response 
to neutral stimuli. 
Acknowledge that majority of 
previous studies using emotional 
paradigms in schizophrenia show 
reduced activation in response to 
emotional stimuli. Suggest the 
difference is due to the fact that 
they used visual stimuli, which are 
less relevant to the symptom 
profile of schizophrenia 
Table 1.1 
Studies employing fMRI to investigate role of the amygdala in schizophrenia 
published after review of Aleman et al.  
 










 Data from children/adolescents has at times been mentioned above, but it is 
important that this is expanded on.  Though a rare condition, there is substantial data, 
and one large longitudinal study, on childhood-onset schizophrenia.  This is defined 
as onset of psychotic symptoms before the thirteenth birthday.  Subjects with this 
condition have more severe premorbid symptoms and a more chronic and severe 
course than later onset individuals.70  Though the childhood age group is largely 
beyond the scope of this study, the fact that manifestations can be so severe in 
children makes it interesting, as anatomical findings might be expected to be more 
pronounced than in adults.  
 The biggest study of childhood onset schizophrenia is that of the National 
Institute of Mental Health (NIMH).  Initial MRI results demonstrated no significant 
differences in amygdala volumes in effected subjects compared to controls (mean age 
14.6 +/- 1.7 years.71  Prospective longitudinal brain MRI rescan measures from the 
NIMH childhood onset schizophrenia sample show progressive abnormalities.  These 
include decreasing temporal lobe volumes 2, 4 and 6 years after the initial scan.  At 
two years, across mean ages 14 to 16 years, though a greater decrease in amygdala 
volume was seen in schizophrenic compared to control subjects, this did not persist 
after adjustment for total cerebral volume.72  When this cohort was followed up at 4 
years post initial scan no evidence for amygdala volume change with age was found 
for either the study or control group.72 
A more recent study of childhood-onset schizophrenia, not based on the 
NIMH data, has produced rather more surprising results.  This study, by Levitt et al 
compared thirteen children with schizophrenia (mean age 14.2 +/- 3.8 years), and 20 
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normal children.70  After adjustment for age and total brain volume, the amygdala was 
larger in the schizophrenic than in the control subjects, and this volume increase was 
more pronounced on the left side.  It must of course be remembered that this is a small 
study and a single result. 
Other studies have examined amygdala volume in subjects with adolescent-
onset schizophrenia.  This data is included with the general discussion of adult data 
where appropriate.  
 
 
1.4 Post mortem studies 
 
 As discussed above, imaging techniques have been widely employed to 
investigate structural abnormalities in the brains of living subjects with schizophrenia. 
For structures such as the amygdala, accurate delineation has only been possible 
following the development of sophisticated technologies such as MRI.  Post mortem 
studies require no such technologies however, and the history of their use in the 
investigation of neuroanatomical abnormalities in schizophrenia has a much longer 
heritage.  If this heritage is to be discussed however, the history of the concept of 
schizophrenia must be appreciated.  This is generally considered to have been first 
defined as dementia precox by Emil Kraeplin in 1896, when he grouped together 
conditions such as hebephrenia and catatonia as manifestations of the same disorder, 
which typically had its onset in early adult life and had a poor outcome.74 
 Early studies investigating coarse brain structure were reviewed by Brown et 
al.75  The earliest relevant study they identified compared brain weights from a group 
of subjects who had had a condition analogous to schizophrenia with those from 
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subjects who had had other psychiatric conditions.  This was undertaken by Crichton-
Brown, dates from 1879, and found brains from subjects with schizophrenia to be 
lighter than, for example, those from subjects who had had an affective disorder.  
Other studies in this review, which date up to the 1960s, generally revealed a 
tendency for schizophrenic subjects to have lower brain weights.  It is of note 
however that in a number of studies there are problems concerning the use of control 
subjects with dementing conditions.74  
 Histological studies were carried out from the late nineteenth century, and 
though several did report abnormalities in the brains of people with schizophrenia, 
there was little consistency among these reports.74  In 1924, Dunlap conducted a 
careful comparison of the brains of eight schizophrenic subjects who died at less than 
45 years of age and five controls, selected in each case for a cause of death that was 
not likely to have influenced the structures of the brain.  No difference in cell counts 
in the cerebral cortex were found between subjects and controls.  This cast scepticism 
over the histopathological literature, but some work did continue, and evidence of 
gliosis and changes in the orientation of cells has been found.74 
 The first identifiable post-mortem study specifically investigating amygdala 
size dates from 1985.  Though it did show reduced amydala volume,76 this was not 
reported in several subsequent studies.77,78  The most recent post-mortem study was 
undertaken by Chance et al and published in 2002.79  They ascertained amygdala 
volume in the brains of 18 patients who had been diagnosed with schizophrenia 
compared to 18 controls.  Clearly this study was limited by the use of elderly, 
medicated subjects, but the advantage of this investigatory technique is that 
delineation of the amygdala could occur at a histological level.  In this small study 
they did not find differences in amygdala size between cases and controls, but as they 
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themselves discuss the study only had a 15% power to detect a change of 5-7% of 
amygdala volume.  The limitations of post mortem studies must not be forgotten when 
interpreting this data.  Obviously this includes potential factors such as differences in 
time from death to tissue fixation between cases and controls and tissue shrinkage.  
The most important limitation however is inherent in the nature of the population 
which must of necessity be studied.  As noted above they are elderly subjects.  As 
well as decades of exposure to neuroleptic medication, they will have been ill for 
many years, and had low levels of physical and mental activity. They, together with 
the control group are likely to have suffered an episode of severe physical ill health 
prior to death.  Thus, even in the case of negative findings on comparing cases to 
controls, the degree to which this refutes that they occur as a consequence of 
schizophrenia itself is questionable.  
 
 
1.6 Synthesis of data addressing abnormalities of the amygdala in schizophrenia 
 
 On reviewing the above it is clear that some of the evidence for amygdala 
abnormalities in schizophrenia is conflicting.  The absence of differences between 
patients with schizophrenia and controls in the most recent post-mortem study, though 
potentially explicable by subject choice and other factors, is still surprising.  Overall 
however, there is much evidence to suggest that amygdala abnormalities are present 
in the brains of schizophrenics.  In addition, there is at least a suggestion, from the 
few pre-illness studies, that these changes may precede illness onset.  There is no 
particular suggestion that the methodological variant of whether or not whole brain 
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volume is controlled for has a significant association with positive or negative 
findings.   
 A further factor apparent from the data above is the suggestion that in 
schizophrenia the left amygdala may exhibit greater or at least earlier volume 
reduction than the right.  Of note, in the Vita et al meta-analysis of first episode 
studies the non-significant trend towards smaller amygdala was greater on the left 
than right side.41  Additionally, in the Honea et al VBM review, which included a 
mixture of first episode and chronic cases, left sided amygdala volume reduction was 
reported to be found in the majority of studies, with no mention of comparable 
reductions on the right side.44  In the study of James et al once again specifically 
smaller amygdala volumes were seen at time of illness onset only on the left side,51 
while VBM analysis of subjects from the EHRS who developed schizophrenia 
suggested that volume loss was more marked on the left side.60  In short, though 
bilateral volume reduction of the amygdala is seen in some studies and meta-analyses, 
















Twin and family studies  
  
 A family history of schizophrenia has long been established as one of the 
strongest risk factors for the disorder in an unaffected proband.80  It is also well 
recognised that schizophrenia is a highly heritable condition, and that brain volumes 
themselves are highly heritable.81  Given these factors it is thus clearly understandable 
why the examination of familial and genetic structural MRI associations has been a 
further area of investigation.  I will summarise below those twin and family studies 
which have relevance to the elucidation of amygdala abnormalities in schizophrenia 
 
Twin studies 
 Studies of monozygotic twins discordant for schizophrenia have the potential 
to distinguish environmental from genetic effects.  Though there are important 
caveats,82 greater neuroanatomical similarities would be presumed to reflect common 
genetic effects and differences to reflect environmental effects.  
 Though few in number, there are studies comparing amygdala volume in 
monozygotic twins discordant for schizophrenia.  One such example is the study of 
Baare et al, which attempted delineation of the amygdala separate from the 
hippocampus.83  It included 15 pairs of discordant monozygotic twins, 14 pairs of 
discordant dizygotic twins and 29 healthy twin pairs.  Unfortunately, due to low 
intrarater reliability, the amygdala data was excluded from analysis.  It was found 
however that irrespective of zygosity, affected co-twins had smaller hippocampal 
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volumes than their healthy co-twin.83  Two more recent twin studies, though they did 
investigate hippocampal volume, once again did not address amygdala volume.84,85  
The study of van Erp et al again found hippocampal volume reduced in the individual 
with schizophrenia in both monozygotic and dizygotic pairs.85  On the basis of their 
analysis they suggest that although hippocampal volumes in healthy twins are highly 
heritable, those in twins discordant for schizophrenia are subject to substantially 
greater modulation by environmental factors.  It is surprising that no twin studies 
could be identified in which amygdala volume is investigated.  Investigation of the 
genetic contribution to amygdala volume by these means has significant potential to 
yield useful data.     
 
Family studies 
 The underlying rationale for investigating the first-degree relatives of patients 
with schizophrenia is that they share approximately 50% of their genome.  As a 
consequence common differences versus controls probably reflect genetic factors, 
while differences between unaffected and affected relatives presumably represent 
disease-specific effects.  There are a number of studies investigating the amygdala-
hippocampal complex, and also some specifically addressing amygdala volume.  Of 
the latter, that of Staal et al is important to discuss.86  It employed region of interest 
methodology to compare volumes of various structure in 32 same-sex siblings 
discordant for schizophrenia and 32 matched controls.  Amygdala volume (together 
with hippocampal) did not significantly differ between patients, siblings and 
comparison subjects.86  This is in contrast to the study of Keshavan et al, again 
specifically measuring the amygdala, in which  volume was reduced in first-degree 
relatives of those with schizophrenia compared to controls.87  A number of studies 
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measuring the AHC have also found it reduced in relatives of those with 
schizophrenia compared to controls.88,89  There is also evidence for smaller AHC in 
those with schizophrenia compared to well relatives.90  
 A refinement of family studies are those focusing on obligate carriers.  The 
rationale for these arises from the fact that although the risk for relatives of 
developing schizophrenia is increased, only a subgroup will actually carry the 
pathological genes.  Thus in multiply affected families affected subjects, non-obligate 
carriers (unaffected, with affected parent but no affected offspring) and obligate 
carriers (unaffected, with affected parent and child) can be identified.  Such a design 
allows a clear separation of the contribution of pathological genes from the effects of 
the disease itself.  In the EHRS AHC volumes (right and left combined) in subjects 
with schizophrenia and obligate carriers were significantly smaller when compared to 
non-affected/non-carriers, which implies a genetic contribution in AHC pathology in 
schizophrenia. 92  These results would suggest that some of the AHC abnormalities 
seen reflect an underlying genetic liability for schizophrenia, rather than being actual 











1.8 The amygdala in schizotypal disorder 
 
 
 As can be seen above, imaging studies focusing on the amygdala in 
schizophrenia have been numerous.  They have included those focusing on subjects at 
high risk before illness onset, first episode subjects and relatives of affected 
individuals.  All of these approaches should reduce the potential of confounding 
factors such as lifestyle and exposure to medication giving rise to any differences 
seen.  It is recognised however that there is a further group of individuals who are of 
interest to the investigation of biological markers associated with schizophrenia. 
These are people with conditions which, due to their commonality with schizophrenia, 
have been grouped as the schizophrenia spectrum disorders.   
Foremost among these disorders is schizotypal personality disorder. This 
condition, similarly to schizophrenia, is characterized by positive or psychotic-like 
symptoms and negative or deficit-like symptoms.  The positive-like symptoms 
include ideas of reference, cognitive or perceptual distortions, and magical thinking. 
Negative symptoms encompass social deficit and interpersonal difficulties.  Cognitive 
disorganisation is also seen.92  As well as symptom similarity there is also evidence of 
a genetic association between the two disorders, with a greater prevalence of 
schizotypal disorder being found in the relatives of those with schizophrenia, and also 
psychophysiological correlates between the two conditions.92 
 Structural imaging findings in the medial temporal regions of individuals with 
schizotypal disorder were reviewed in Siever et als American Journal of Psychiatry 
review of 2004.92  They note that though some temporal lobe structures have been 
found to be reduced in schizotypal subjects compared to controls,  this reduction was 
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not seen in the medial temporal lobe, and in one, albeit small adult study, no 
difference was seen in the specifically measured amygdala.93  In contrast to these 
results, a Japanese study comparing 59 controls, 25 schizotypals and 59 
schizophrenics found that both amygdala and hippocampal volumes were reduced 
bilaterally in both subjects with schizophrenia and schizotypy compared to controls.40  
A VBM study by Kawasaki et al in the same centre, and with considerable overlap of 
subjects, compared 25 subjects with schizophrenia, 25 schizotypal subjects and 50 
controls.94  Patients with schizotypal disorder again showed grey matter reductions in 
the medial temporal region compared to controls.  It should be noted however that in 
these studies schizotypal patients were recruited from already being in contact with 
services and the majority were receiving medication, and thus somewhat different 
from other schizotypal groups.  Despite this limitations however, there are additional 
interesting findings from these studies.  Not least of these is data from the Suzuki 
study concerning scores on the Scale for the Assessment of Negative Symptoms 
(SANS) and prefrontal cortex volumes.  Though prefrontal cortex subcomponent 
volumes were reduced in those with schizophrenia, this was generally not the case in 
schizotypal subjects.  This was despite the fact that schizotypal subjects scored as 
highly as schizophrenic subjects on the SANS.  This does not seem compatible with 
the widely accepted belief that prefrontal cortical volume loss is associated with 
negative symptoms in schizophrenia.   
 Functional studies also suggest differences between patients with schizotypy 
and controls.  Similar to schizophrenic patients, Mohanty et al report increased 
activity in the hippocampal and amygdalar regions during performance on an 
emotional Stroop test in patients with positive schizotypy compared to controls.95 
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 A further means of investigating the relationship between schizotypal 
symptoms and schizophrenia is to establish the prevalence of these symptoms in 
individuals at high risk for schizophrenia.  This was done in the EHRS, in which it 
was determined that higher scores on the Structured Interview for Schizotypy (SIS)96 
indicated increased risk of developing schizophrenia.97  As part of this study the 
relationship between high scores on measures of schizotypy and neuroanatomical 
abnormalities, including those of the AHC was also investigated.  Analysis of the high 
risk group within the EHRS failed to show a clear correlation between score on the 
SIS or Rust Inventory of Schizotypal Cognitions (RISC)98 scores and AHC size.99 
 
 
Implications of findings relating score on measures of schizotypy to vulnerability to 
developing schizophrenia  
 
 As mentioned above, within the high risk group of the EHRS, those scoring 
higher on the SIS were at elevated risk of developing schizophrenia, with certain 
factors, such as oddness and social withdrawal having particular predictive power.97 
Higher scores on the CBCL, a scale measuring childhood behavioural disturbance 
also predicted greater likelihood of developing schizophrenia.97  This means that by 
employing these tools, from within a group already at elevated risk of developing 
schizophrenia, those whose risk is elevated further still can be identified.  As will be 






1.9 Schizophrenia and learning disability 
 
 
1.9.1 Nature of the association 
 
 One of the aims of the EHRS, discussed in some detail above, was to try to 
establish if there was a potential way to identify individuals who may go on to 
develop schizophrenia.  This would clearly have great utility, as preventative 
interventions could then be targeted to this group.  In the EHRS the group targeted for 
study were those with an increased risk of developing schizophrenia by virtue of their 
family history.  A further group known to be at elevated risk of the condition, but little 
studied as a high risk population, is those with learning disability. 
 It is acknowledged that at all stages of schizophrenia, premorbid, pre-illness, 
acute and chronic illness there is a relationship between schizophrenia and 
impairments in cognitive ability.100  It is also well recognised that in people with mild 
learning disability (LD) there is an increased prevalence of schizophrenia. Within this 
group the point prevalence is 3%, three times that of the general population.101  This 
acknowledgement of an association between schizophrenia and learning disability is 
not new.  In 1919 Kraepelin described propfschizophrenie, a condition in which 
dementia praecox arose in a setting of pre-existing intellectual impairment.102  He 
stated that dementia praecox could be diagnosed in 7% of people with learning 
disability, that the psychosis had a very early onset and that the pathological process 
involved in this actually led to the intellectual disability.  
The association between schizophrenia and learning disability could of course 
result from various possibilities.  The direction of association must either be however 
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the presence of schizophrenia (diagnosed or destined to develop) increasing the 
likelihood of an individual being diagnosed as having a learning disability or the 
presence of a learning disability increasing the likelihood of an individual being 
diagnosed as having schizophrenia.  The latter possibility implies that the cognitive 
deficits of some individuals with learning disability convey an increased susceptibility 
to develop the impairments associated with schizophrenia, the suggested mechanism 
being the overload on comprehension imparted by partly understood stimuli.103  The 
former possibility is consistent with the view that cognitive dysfunction, and 
sometimes motor and social impairment, in children may be the initial symptoms of 
severe schizophrenia.  
 In an attempt to clarify which of the above possibilities was most likely, 
studies were undertaken comparing subjects with co-morbid schizophrenia and 
learning disability to individuals with learning disability alone and schizophrenia 
alone in terms of clinical, imaging and genetic parameters.103,104  Structural brain 
changes in the co-morbid sample were reported to strongly resemble those of the 
schizophrenia sample and be very different from the group with learning disability 
alone.  One such commonality was the finding of smaller AHCs relative to whole 
brain size.  Whole brain volume was controlled for in this study, and indeed while 
similar in the comorbid and schizophrenic groups, differed significantly from those in 
the learning disabled group.  On the basis of the above and other data, it was 
postulated that co-morbidity represents a severe form of schizophrenia.  This opens 
the possibility that within the young learning disabled population there may be 
individuals whose cognitive difficulties are part of the natural history of an illness 
where the clinical features that define schizophrenia have yet to become manifest.  
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1.9.2 Clarification of clinical features of schizophrenia in learning disability 
 
 In Doody et als paper, comparing schizophrenia in those with mild learning 
disability to that in those with normal IQ, a number of clinical differences were noted 
between the two groups.103  Among these was a significant difference in rating on the 
negative subset of the Positive and Negative Symptom Scale (PANSS).  Though the 
comorbid group showed no differences in positive, general or total symptom profiles 
compared with the schizophrenic control group, they did have significantly more 
negative symptoms.  This is an intriguing finding, particularly in the context of co-
occurrence of schizophrenia and learning disability being proposed as a specific 
manifestation of a severe form of schizophrenia.  Given this I undertook a systematic 
review of psychopathology in schizophrenia associated with mild or borderline 




 Medline, EMBASE and PsychINFO were searched for all English language 
studies published between January 1984 and March 2007 that compared clinical 
features of schizophrenia in people with learning disability or borderline intellectual 
impairment and those with normal IQ.  The search terms were schizophrenia 
combined using the AND operator with learning disability, mental retardation, or 
intellectual impairment, AND   symptoms, or psychopathology.  Both free-text 
and expanded medical subject headings were used.  Subject headings were adapted to 
the specific subject headings of the biomedical databases used.  The search strategy 
was supplemented by inspecting the reference lists of included articles.   
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Criteria for inclusion 
 Abstracts were assessed for inclusion by the author, and articles in full text 
were retrieved if appropriate.  Primary research studies were considered for inclusion 
if they were published as a peer-reviewed article in English and compared learning 
disabled or borderline learning disability subjects with schizophrenia with those of 
normal IQ.  Additionally, they required to use a recognised symptom rating scale (i.e. 
BPRS, PANSS, SANS) to quantify symptoms including the negative subset.  
 
Results 
 108 articles were identified through the database search.  Only five of these, 
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of NART score.  
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intellectual 
impairment group 
had higher scores on 
positive (p = 0.004) 
and negative 
(p<0.001) symptoms 
scales of PANSS  
Table 1.2  
Studies investigating the clinical features of schizophrenia in learning disabled 
populations 
 
Abbreviations: CPRS, Comprehensive Psychopathological Rating Scale; SANS, Scale 
for the Assessment of Negative Symptoms; PANSS, Positive and Negative Syndrome 
Scale 
 
¹ Borderline intellectual impairment refers to IQ in range 71-81 





1. Lack of data 
 As can be seen from the table, there is a paucity of studies investigating the 
clinical presentation of schizophrenia in learning disability/intellectual impairment.  A 
number of explanations can be postulated to account for this.  One reason may be that 
historically people with learning disabilities were seen as being incapable of suffering 
from mental illness.107  This has been strongly refuted by more recent epidemiological 
studies.101  Even after this realisation however, studies remained few.  This may be a 
consequence of the fact that the Meadows et al study, one of the earliest addressing 
the clinical presentation of schizophrenia in people with LD, indicated a clinical 
picture much like that of people without LD.105 
 
2. Difficulties in assessing symptom profile in learning disability 
 It is accepted that the diagnosis of schizophrenia in people with learning 
disability is hampered by the difficulty of getting clear descriptions of first rank 
symptoms.  Additionally, negative symptoms have the potential to be confused with 
depression and behaviour which may occur in people with LD who are not mentally 
ill at all.109  In mild learning disability however, a number of the widely used 
structured interviews and rating scales have been shown to have validity,105,110 and it 
is generally accepted that in this population symptoms can be characterised with 
acceptable accuracy.  The possibility that negative symptoms are an expression of 
learning disability rather than schizophrenia can be addressed by including a non-
schizophrenic learning disabled control.  This was done in the Doody et al study, in 
which it was shown that this group actually scored very low on this symptom 
subset.103  
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3. Main findings 
 The most consistent finding from the above studies is that the comorbid group 
experience a greater weight of negative symptoms.  There are a number of possible 
explanations for this, two being that this group have a longer duration of illness or that 
they progress more rapidly to a deficit state.  In studies that have either matched for 
illness duration or it is equal, the comorbid group continue to score higher on this 
symptom subset.107  This would thus suggest that there is indeed something intrinsic 
to schizophrenia in the intellectually impaired group which increases the likelihood of 
reaching a deficit state.        
 
4. Relevance of findings to study proposal 
 Central to the design of the current study is the idea that co-morbid 
schizophrenia and learning disability represents a severe schizophrenia, in which 
clinical features, amongst others, are more marked.  The finding of more marked 
negative symptoms in this population is consistent with this concept.  Indeed, in a 
number of these papers it is explicitly discussed that the combination of intellectual 
disability and schizophrenia could represent a distinct subgroup of people with 
neurodevelopmental schizophrenia and intellectual impairments.107,108       
   
 
 
1.9.3 Implications of the concept of a severe schizophrenia for research 
 
 The essence of the findings discussed in Section 1.9.1 is essentially that the 
presence of a schizophrenic diathesis might form the underlying basis of evident 
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cognitive impairment in some of the young learning disabled population.  If this was 
indeed the case then within the learning disabled population would be some 
individuals whose learning disability represented a schizophrenic illness in which 
psychotic symptoms had yet to become manifest.  Within the wider population of 
people with learning disabilities affected individuals are likely to be only a small 
minority (~3%).  Examining the whole population at risk over the period of 
vulnerability for schizophrenia would not be practical.  Findings from the EHRS 
however suggested a means whereby identification may be facilitated and the issues 
examined within a pragmatic time frame. 
 
 
1.9.4 Implications of findings from the EHRS for the identification of learning 
disabled subjects at elevated risk of developing schizophrenia 
 
 The EHRS showed that scores on the Child Behavioural Checklist,113 (based 
on parental accounts) and the Structured Inventory for Schizophrenia,96 (based on 
subjects own accounts) were significant predictors of the development of psychotic 
symptoms and  ultimately among the most important predictors of the later 
development of a formal schizophrenic illness.97,111,112  As discussed above, though 
the clinical picture may be more severe in the latter population, there appears to be 
marked commonality between schizophrenia in the population with normal 
intelligence and that in the learning disabled population.104  It may thus be possible, 
by employing the CBCL and SIS, to identify from within the population with mild 
learning disability those at elevated risk of developing schizophrenia.  By these means 
a cohort of learning disabled individuals of manageable size can be identified for 
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1.10 The amygdala in learning disability 
 
 
 If amygdala volume in learning disabled subjects at high risk for 
schizophrenia is to be investigated, then it is important to clarify what is known about 
amygdala volume in non-schizophrenic learning disabled subjects.  For this reason a 




Systematic review of studies investigating amygdala size in learning disability 
 
 Medline, EMBASE and PsychINFO were searched for all English language 
studies published between January 1984 and March 2007 that reported structural MRI 
data on the amygdala in learning disability.  Search terms included learning 
disability, intellectual impairment and mental retardation combined using the 
AND operator with amygdala.  Both free-text and expanded medical subject 
headings were used.  Subject headings were adapted to the specific subject headings 
of the biomedical databases used.  The search strategy was supplemented by including 
a cited reference search and inspecting the reference lists of included articles.  Articles 
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of interest were those concerning the imaging of individuals with idiopathic learning 
disability, with or without schizophrenia.  
 Initial search yielded 128 articles.  On review of these abstracts however, only 
three articles were appropriate for inclusion.  Common exclusion criteria were articles 
addressing defined syndromes associated with learning disability, such as Downs 
syndrome.  The three articles identified were all from the Edinburgh group and 
discussed the same cohort investigated by Sanderson, described above.  Learning 
disabled controls were included, and as part of a battery of investigations AHC 
volume determined.  One of these studies concerned VBM analysis of the same scans, 
the other two discussed the same imaging data.  Findings from these publications of 
relevance to this study are detailed below. 
 
Significant findings from Sanderson et al, comparing neuroanatomy in a comorbid 
learning disability/schizophrenia group with learning disabled, schizophrenic and 
normal controls by ROI methodology: 
 
1. After controlling for the effects of whole brain volume, left and right AHC 
significantly smaller in comorbid group than in learning disability group and normal 
controls. 
2. After controlling for whole brain volume, left AHC significantly larger in learning 
disabled than normal controls 
3.Greater right/left difference in AHC size in normal controls 
 
Table 1.3 






Significant findings from Moorhead et al, comparing neuroanatomy in a comorbid 
learning disability/schizophrenia group with learning disabled, schizophrenic and 
normal controls by VBM methodology. Data was analysed by both normalized and 
native space analysis; the former controls for whole brain volume, while the latter 
mirrors ROI analysis uncorrected for whole brain volume. 
 
 
1. Both the left amygdala and left hippocampus were significantly smaller in 
comorbids than normal controls by analysis in normalized space, i.e. correcting for 
whole brain volume. 
2. By analysis in normalised space deficits the left amygdala was significantly smaller 
in the schizophrenic group compared to normal controls. 
3. By analysis in normalized space no significant differences were seen between the 
schizophrenic and comorbid group in volumes of the temporal lobe or amygdalo-
hippocampal complex. Overall, this together with other evidence suggested that 
comorbids and schizophrenics belonged to the same population. 
4. Analysis in native space, not correcting for whole brain volume, was also indicative 
of similarities between the comorbid and schizophrenia groups. This is consistent with 
the view that comorbid learning disability and schizophrenia is a severe form of 
schizophrenia. 
5. They note that the process of native space analysis could result in a failure to 


















1.11 The Edinburgh Study of Comorbidity 
 
 
 The Edinburgh Study of Comorbidity (ESC) is a large, ongoing prospective 
study which applies the findings discussed above to the longitudinal assessment of a 
group of adolescents with special educational needs largely through the presence of a 
mild or borderline learning disability.  As discussed above, by virtue of this cognitive 
impairment they are already at elevated risk of developing schizophrenia.  From this 
group, by application of the CBCL113 and SIS96, those individuals at highest risk of 
developing the illness should be identifiable. They can then be subject to detailed 
investigation. Clearly the assumption in employing this methodology is that the two 
populations (the genetic high risk population in the EHRS, and the cognitively 
impaired high risk population in the ESC), will prove to show similarities in terms of 
the pattern of illness development.     
 
 
The current study 
 
 This study concerns a subset of the baseline sample acquired for the ESC. The 
groups within that sample that I will be discussing are those at highest risk for 
schizophrenia (learning disabled, CBCL+ and SIS+) and the unrelated, non-learning 
disabled control group.  From the baseline MRI scans of these individuals amygdala 
volume was determined.  This can then be compared between the two groups, and any 
associations between amygdala size and findings on neuropsychological and 




















































 The recruitment process is summarised in Figure 2.1.  Recruitment was via 
schools and colleges across 18 out of the 19 Educational Authorities in Scotland 
which are within reasonable travelling distance of Edinburgh (one Educational 
Authority declined to participate).  Of the 273 schools and colleges approached 99 
agreed to enter the study.  The head teachers of these schools were asked to identify 
adolescents receiving special educational assistance, in particular those with a 
presumed IQ in the range 50-80.  Exclusion criteria at recruitment were known 
syndromic learning disability, severe cerebral palsy, profound learning disability, lack 
of speech and a known brain injury.   
 Parents of the adolescents identified were then invited to participate in the 
study by letter.  Five hundred and one individuals initially agreed to participate 
although in 36 of these cases, the family subsequently withdrew from the study.  The 
CBCL was, therefore, completed on 465 subjects by one of the research team visiting 
the home and interviewing the parents.  The CBCL has been validated for use in those 
with learning disability.115  Of these 465 participants, 42 were excluded and an 
additional 28 did not participate further (see Figure 2.1).  394 of the 395 were 
assessed using the Structured Interview for Schizotypy (SIS) (one participant did not 
complete the SIS).  The SIS has not been widely used in the learning disabled 
population, but a pilot study undertaken by the investigators had confirmed the 
feasibility of using this tool in the population (there were no subjects in whom the 
interview could not be conducted and satisfactory inter-rater reliabilities were 
obtained.100  
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 Cut-offs on the scales discussed above, which were found to predict the later 
development of schizophrenia in the Edinburgh High Risk study,97 were used to 
identify those suitable for recruitment into the next phase of the study for more 
detailed assessment.  The average scores on the SIS and the CBCL were higher in this 
population than in the Edinburgh High Risk Project therefore the cut-off points were 
scaled up appropriately.100  Participants were evenly sampled into 4 groups based on 
these cut-offs  SIShighCBCLhigh, SIShighCBCLlow, SISlowCBCLhigh and SISlowCBCLlow.  
In addition to the subjects receiving special educational assistance a control group 
consisting of young people from the same environment was also recruited.  The 
controls had no history of receiving educational assistance or of major psychiatric 


























































Summary of the recruitment process 
36 subjects score above cut 
offs on CBCL and SIS 
28 unrelated 
controls have MRI 
scan 
99 out of 273 schools and colleges 
501 individuals receiving special educational assistance 
64 withdrawals 
42 exclusions 
1 incomplete assessment 
394 subjects receiving 
special educational 
assistance 
Assessment with SIS and 
CBCL and sampling into 
four groups based on scores 
Participants in youth and 
voluntary associations 
approached and invited to 
take part 
32 subjects have baseline 
MRI scan  
28 unrelated 





28 subjects right and left 
amygdala volumetry 
achieved 
1 scan lost, 
3 scans  
untraceable 
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 Following the baseline assessment, generally four to six months later, 
participants attended for a psychiatric interview and neuropsychological assessment. 
The neuropsychological testing strategy was tailored to accommodate specific age and 
ability issues, with an emphasis on memory and executive function.  The WISC and 
WAIS (as appropriate to the individuals age),116,117 were used to determine IQ in all 
participants at baseline.  Subsequent tests were only undertaken in subjects and not 
repeated in controls.  Amongst these tests was assessment of mental state.  The 
Clinical Interview Schedule (CIS)118 was chosen for this task rather than the long and 
complex Present State Examination.  It is relatively brief, covers key areas for 
establishing caseness in major psychiatric disorders with reliability, and is more 
acceptable to young and particularly to intellectually impaired individuals.119  
Psychotic phenomena were sub-classified as per Goldberg and co-workers in their 
modification for psychotic subjects.120  The Positive and Negative Syndrome Scale 
(PANSS) was also included because of its widespread use.121  All clinical ratings were 
done blind to CBCL/SIS cell allocation. 
 After clinical assessments, subjects had a structural MRI scan.  It was from a 
subset of these scans, those from the CBCL+/SIS+ group and the unrelated control 
group, that amygdala volume was determined.  Of the 36 subjects identified as being 
in the SIS+/CBCL+ group, 32 were recruited to this part of the study.  Of these 32 
subjects who were scanned, in the scans of three the amygdalae could not be traced. 
The reason for this in all three cases was that subjects had been wearing a brace, 
which obscured the images of the medial temporal lobe structures.  One further scan 
was lost.  As can be seen in Figure 2.1, the right and left amygdala of 28 subjects 
were thus successfully traced.  Twenty eight control subjects were also identified and 
right and left amygdalae successfully traced. 
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2.2 MRI scanning: Acquisition of scans 
 
 MR imaging was performed at the SHEFC Brain Imaging Research Centre for  
Scotland on a 1.5T GE Signa Echospeed system (GE Medical Systems, Milwaukee, 
Wisconsin) operating in research mode consisting of a T1-weighted sagittal sequence 
with parameters of 16/450/0.75 (TE/TR/excitations) and a T2-weighted axial 
sequence with parameters of 102/6300/2.  Volume data was obtained with a 3D 
inversion-recovery prepared T1-weighted sequence with parameters of 3.3/8.1/1, TI 









 In vivo assessment of amygdala volume by magnetic resonance imaging is 
generally recognised as challenging.  Unfortunately, the amygdala and structures 
surrounding it have similar signal intensities, a fact which makes accurate delineation 
of amygdala boundaries difficult.  Perhaps unsurprisingly therefore, a striking feature 
of studies that have addressed the measurement of the amygdale in subjects with 
schizophrenia is the wide range of volumes encountered.  This is equally true of 
studies in normal subjects, with reports of volumes ranging from 1 to 4 cm³.122  
Another striking finding is the variety of protocols that have been devised with the 
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aim of achieving reliability in amygdala measurement, and the variety of different 
landmarks utilised in these.  Despite these obvious difficulties, for this study to have 
validity it is essential that an accurate method for identification and delineation of the 
amygdala can be employed. 
 Brierley et al published a systematic review and meta-analysis of amygdala 
volumetric magnetic resonance imaging in 2002.123  Their aim was to estimate the 
normal range of amygdala volume in adults and to account for the heterogeneity of 
previously reported measures.  Among other factors, they considered subject and 
methodological variables, positional and volume correction and the reliability of 
measurement.  They discuss the tendency, given that amygdala borders are not clear, 
for methodologies to tend to rely on external landmarks to improve reliability.  
Clearly this means that individual anatomical variation can influence measures of 
amygdala size.  
 The Brierley study used a wide variety of studies to provide data on 
volumetric MRI of the adult human amygdala in non-clinical subjects.  Studies were 
only included if there was adequate description of the methodology employed in the 
anatomical definition of the amygdala or a suitable reference cited and volume 
measures were not given in combination with the hippocampus.  These studies 
utilised various measurement protocols, and thus enabled comparison of anatomical 
definitions of the amygdala.   
 Brierley et als review included 39 publications.  They found that the main 
methodological factor found to influence amygdala measurement was anatomical 
definition.  Of the various methodologies employed to delineate the amygdala in these 
studies, Watsons124 was employed in a third.  When 95% confidence intervals for 
both right and left amygdala volumes obtained by these criteria were compared to 
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those obtained by non-Watson criteria, there was no overlap.  The former method 
yielded measurements of 2384-2539.6mm³ and 2219.3-2373.7 mm³ for left and right 
amygdala respectively, while with the latter methods these figures were 1612.2-
1690.6 mm³ and 1582.4-1667.0 mm³.  
 As discussed above, it is clear that significantly greater volumes are generated 
by employing Watsons criteria.  Given the heterogeneity of the non-Watson group, 
it is difficult to compare the sets, but what is apparent on studying Watsons criteria is 
that they rely heavily on external landmarks.  It thus seems evident that that means of 
determination of boundary definition will have an impact on amygdala size, and it is 
conceivable that heavier reliance on external landmarks could skew amygdala volume 
estimation.  It must be remembered that the individuals included in this study were 
non-clinical subjects.  If we are to accept the suggestion of Breierley et al, that for 
reasons of consistency Watsons criteria should be employed, then we are also 
assuming that this practice is equally applicable to clinical subjects.  
 The issue of reliance on external landmarks in amygdala measurement, and its 
influence on amygdala size estimation in clinical subjects is further discussed in the 
paper of Chance et al, also of 2002.79  They reflect on the potential pitfalls of 
employing this technique when schizophrenia is known to be associated with 
significant anatomical variations from normal.  For example, it is reported that 
temporal lobes are shortened in this condition; if this is the case, then landmarks that 
lie outside the temporal lobe will be further forwards relative to structures within the 
temporal lobe.  Consequently, the use of external landmarks in MRI studies could 




Review of methodologies employed in delineation of the amygdala from 2004-2007 
 
 From the discussion above it seems clear that, in subjects who are not normal 
at least, there is an argument against the widespread adoption of Watsons criteria. 
For these subjects methods of volume estimation from MRI images that are less 
dependent on external landmarks would seem to have advantages.  To determine what 
has been general practice in recent years (when it should be more viable to be less 
dependant on external landmarks, given greater scan resolution), I undertook a review 
of methods of amygdala measurement that have been employed within the three year 
period from 1st January 2004 to 1st January 2007.  As Brierley et als meta-analysis 
was published in 2002, the bulk of studies published within this time period would 
likely have commenced after this publication was available.  The first aim of this 
review was to establish if consensus on anatomical delineation of the amygdala has 
occurred.  If this is the case then it would be reasonable to employ this methodology 
in this study.  If this consensus has not occurred, then this review will also assist in 
identification of an appropriate methodology to utilise in this study.  This would 




 In the case of Brierley et als extensive review, their computerised literature 
search using Medline and dating up to February 2001 was performed using 
amygdala, combined with magnetic resonance imaging as search terms.  On 
running a search with the same parameters on PubMed for the three year period 1st 
January 2004 to 1st January 2007, 507 articles were identified, of which 59 were 
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review articles.  Review of this number of abstracts was beyond the scope of this 
work, and so a further search was run to try and focus on those articles more likely to 
have directly addressed the issues involved in measurement of the amygdale.  For this 
purpose a search was run using the key word amygdala combined with the AND 
operator with  magnetic resonance imaging AND measurement or volume or 
protocol. This identified 178 articles, of which 14 were reviews.  Inclusion criteria 
were that the study was printed in English and employed structural MRI and region of 
interest methodology to determine volume of the amygdala.  On review of these 
abstracts 42 papers seemed appropriate for inclusion, but only 31 were obtainable in 
full text form.  As the main role of this review was simply to gain an impression of 
the range of techniques employed in amygdala delineation in this time period, this 
seemed a reasonable yield.  The papers were reviewed to determine the technique 
employed in amygdala delineation.  If this was not clear, then this is stated in the 
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Discussion of range of methodologies employed 
 
 On review of the data above it is clear that, despite Brierleys paper, consensus 
regarding the technique that should be employed in delineation of the amygdala has 
certainly not been reached.  It is the case that of all methodologies Watsons is the 
most prominent; it was the single most used technique, being employed in 6 of the 31 
studies.  The methodology described by Convit154 was second most commonly used, 
being chosen in 4 studies.  In a total of five studies the methodology employed was 
far from clear.  
 As there is clearly no consensus on techniques employed, it is important to 
consider the merits of the various methodologies.  As outlined by Chance et al, and 
discussed above, the extent to which a methodology relies on external landmarks 
influences its susceptibility to the introduction of systematic bias.79  Of the techniques 
discussed, Convit et als does try and minimise use of external landmarks, though 
they are employed in determination of the anterior extent.  Pruessners technique is 
more dependant on external landmarks, particularly for the superomedial amygdala.122  
The landmarks employed in Schumanns technique abut directly on to the 
amygdala.128  This should mean that the influence of anatomical abnormalities in 
calculation of amygdala volume are minimised.  This technique also managed to 







Implications of review for methodology employed in this study 
 
In the present study the aim was to compare amygdala size in a group with 
learning disability and various other markers of elevated risk for schizophrenia with 
normal controls.  The former group is clearly likely to have abnormalities of brain 
structure.  It does thus seem that, at least if satisfactory reliability could be achieved, a 
method of delineation of amygdala boundaries which did not rely on external markers 
would be optimal.  This would prevent abnormalities of structures surrounding the 
amygdala skewing amygdala measurements.  On this basis the protocol for amygdala 
measurement as outlined in the Appendix was devised.  Though there are some 
modifications, it relies heavily on the methodology outlined by Schumann.128  
Reliability (intraclass correlation coefficients) of measurements using this protocol 
was then established.  Either right or left amygdalae from seven brains (selected at 
random) were traced twice to establish intra-rater reliability.  Ten amygdalae (again 
selected at random) were also traced by a second investigator (AS) to establish inter-
rater reliability.  Inter-rater reliability was 0.80 and intra-rater reliability 0.88.   I 




2.4 Statistical analysis 
 
 All statistical analyses were carried out using SPSS 14.0 for Windows.  
Differences between the demographic characteristics were assessed using t tests and 
chi sq as appropriate.  The amygdala volume data were evaluated to determine the 
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appropriateness of using parametric statistics.  The distribution of the data was 
approximately normal, and the ratio of standard deviation to mean compatible with 
normalcy in all groups.  The appropriateness of employing parametric statistics is 
discussed in more detail in Chapter 4.  Mean amygdala volume in the two groups was 
compared using the independent t-test, both with and without modification for 
unequal variances.  Given that this inequality of variance did exist between the two 
groups, (that in the unrelated controls was just over double that in the subjects), I also 
undertook this comparison using non-parametric statistical methods.  Thus, I also 
compared amygdala volume in the two groups with the Mann-Whitney U-test.  This 
enabled comparison of the results both with and without the assumption of equal 
variance and with and without the assumption of normalcy.  As will be seen in 
Section 3.1, the results of all three analyses were similar.  Separate analyses of 
covariance (ANCOVA) were used for each hemisphere to examine for differences in 
amygdala size between the groups.  Amygdala size was the dependent variable with 
group and gender as fixed factors.  The analysis was repeated with the addition of 
whole brain volume as a covariate. Standardised residuals were checked for 
normality.    
 
Analysis of within study group differences was also undertaken. The 
associations between amygdala size and scores on symptom scales and the 
relationships between age and amygdala volumes within the study group were 
examined using partial correlations covarying for whole brain volume and gender.  
The relationships between age and symptom ratings in each group were assessed 

























































3.1.1 Descriptive data 
 
 The basic characteristics of gender, age at first assessment, height, IQ, scores 
on the CBCL and SIS and whole brain volume of the two groups under study are 
detailed in Table 3.1. A summary of statistical comparison is also included.  As 
expected, given that the group was selected on the basis of scores on these tests, the 
CBCL+/SIS+ group has significantly higher mean scores on the CBCL and SIS than 
the control group.  Also unsurprisingly, the unrelated control group had significantly 
higher mean IQ.  Comparison between groups of height, age at first assessment and 
whole brain volume revealed no significant difference.  Comparison of gender did 
however, with males being over-represented in the study group.  This reflects the 
substantial difficulties in recruiting male control subjects for the study.  
 
 
 CBCL+/SIS+ Controls P value 
Age at first 
assessment 
16.1 (1.9) 16.6 (1.7) 0.32 
Number of 
subjects 
28 28  
Height 166.9 (9.6) 169.5 (8.8) 0.30 
Full IQ 74.6 (18.0) 107.4 (15.3) 0.00 
Gender (M:F) 20:8 10:17 0.01* 
SIS 38.5 (8.0) 19.3 (5.4) 0.00 
CBCL 111.8 (17.9) 13.9 (12.4) 0.00 
Whole brain 
volume 
1352745 (176082) 1359057 (147109) 0.89 
Table 3.1 
Demographic characteristics, IQ and mean CBCL and SIS scores for subjects and 
controls.  
Aside from for gender results are shown as mean (standard deviation).  
Statistic is independent samples t test aside from * which is chi squared. 
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3.1.2 Comparison of amygdala volumes 
 
 
 Descriptive statistics of amygdala volumes are summarised in table 3.2.  Data 
for right and left amygdale are displayed separately as there is substantial data 
suggesting that there is asymmetry of amygdala size.44,51  Mean amygdala volume for 
males and females has been combined. 
 
 Left amygdala Right amygdala 
 CBCL+/SIS+ Controls CBCL+/SIS+ Controls 
Number of 
subjects 
28 28 28 28 
Mean 1405.3 1282.9 1436.4 1288.3 
Standard 
deviation 
334.9 158.7 386.5 135.5 
Median 1498.8 1254.2 1435.0 1291.3 
Range 1394.9 576.3 1843.1 572.5 
Table 3.2.  
Raw amygdala volume (mm3) in CBCL+/SIS+ and control subjects. 
 
 
 As can be seen from table 3.2, mean amygdala volume is greater in the study 
than control group.  The significance of this difference in the raw data was 
investigated using both parametric (independent t-test) and non-parametric (Mann-
Whitney U-test.  The independent t-test was employed both with and without 
modification for unequal variance.  The rationale behind using both tests is discussed 
in Section 2.4, and results shown in tables 3.3 and 3.4. 
 As can be seen in Table 3.3, the difference in volume between the study and 
control groups was close to significance.  This was particularly the case for the right 
amygdala, the level of significance seen being similar both when parametric and non-
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Comparison of raw amygdala volumes in SIS+/CBCL+ and control subjects by the 
independent t-test both with and without the assumption of equal variances. 
 






Z score Sign. 
Left amygdala 32.04 24.96 897.00 699.00 -1.62 0.105 
Right amygdala 32.50 24.50 910.00 686.00 -1.84 0.066 
Table 3.4 





3.1.3 Comparison of amygdala volume with adjustment for potential confounders 
 
 
 As can be seen in Table 3.1, there is a gender imbalance between the study 
and control groups and they also differ (albeit to a lesser extent) in whole brain 
volume.  To enable these differences to be taken into account in the analysis, analysis 
of covariance was undertaken.  Amygdala volume was the dependent factor, group 
and gender fixed factors, and whole brain volume a covariate.  Analysis was repeated 
with full IQ as an additional covariate.  Results are shown in Tables 3.5 and 3.6. 
Mean amygdala volume   
SIS+/CBCL+ Controls 
F statistic Significance 
Left amygdala  1400.9 1280.1 2.949 0.092 
Right amygdala 1402.7 1277.2 2.425 0.126 
Table 3.5  
Comparison of amygdala volume in study and control groups by ANCOVA with 
covariation for gender and whole brain volume. 
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Mean amygdala volume   
SIS+/CBCL+ Controls 
F statistic Significance 
Left amygdala  1429.7 1254.5 3.615 0.063 
Right amygdala 1466.2 1200.9 5.663 0.021 
Table 3.6 
Comparison of amygdala volume in study and control groups by ANCOVA with 
covariation for gender, whole brain volume and full IQ. 
 
As can be seen in Table 3.6, when IQ is included as a covariate the volume of the 
right amygdala is larger in the study group compared to the controls to a statistically 
significant degree.  Overall however covariation for IQ was no felt to be appropriate 










3.2.1 Relationship between amygdala volume and score on PANSS 
 
 Correlation between amygdala volume, (after covariation for gender and 
whole brain volume), with PANSS score is shown in Table 3.7.  As well as total 
PANSS score, scores on the positive symptom, negative symptom and general 



















Correlation -0.048 -0.511 0.062 -0.308 Left 
amygdale Significance 0.821 0.009 0.767 0.134 
Correlation -0.051 -0.261 0.071 -0.110 Right 
amygdale Significance 0.810 0.208 0.735 0.600 
Table 3.7 
Correlation between score on PANSS and amygdala size within the study group after 




A significant correlation was seen between score on the negative subset of symptoms 
on PANSS and left amygdala size covaried for gender and whole brain volume.  This 
correlation is shown graphically in Figure 3.1.  This correlation remained significant 








Relationship between score on PANSS negative symptom subset and left amygdala 





3.2.2 Relationship between amygdala volume and score on CBCL 
 
 
 Correlation between amygdala volume, (after covariation for gender and 
whole brain volume), and score on the CBCL is shown for the SIS+/CBCL+ group in 
Table 3.8.  As can be seen the correlation was not significant.  This remained the case 




 Correlation  Significance 
Left amygdala 0.199 0.329 
Right amygdala 0.062 0.764 
Table 3.8 
Correlation between score on CBCL and amygdala volume within the study group 




3.2.3 Relationship between age and score on symptom scales. 
 
 
 The relationship between age and scores on symptoms subgroups as measured 
by PANSS was also examined for the study group and the results are shown in Table 
3.9.  As can be seen a significant relationship was seen between age and score on the 
PANSS positive and general subsets, and a highly significant relationship between 
age and score on the PANSS total and PANSS negative subsets.  The relationship 
between score on the negative symptom subset of PANSS and age is shown in Figure 











0.427 0.638 0.473 0.658 
Significance 0.026 <0.001 0.013 <0.001 
Table 3.9  













3.3 Comparison of relationship between volume of left and right amygdala and 
age in the study and control groups 
 
 
As is discussed above, there is a significant association between increasing age 
and greater weight of negative symptoms.  There is also a significant association 
between greater weight of negative symptoms and reduced left amygdala volume 
within the study group.  This naturally leads to speculation about the relationship 
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between age and amygdala volume. Investigation of this relationship is detailed in 
Table 3.10. 
 
  Correlation Significance 
Left amygdala -0.325 0.106 CBCL+/SIS+ 
Right amygdala -0.175 0.393 
Left amygdale -0.120 0.560 Controls 
Right amygdala 0.134 0.513 
Table 3.10 
Correlation between amygdala volume and age in the study and control groups. 
Gender and whole brain volume have been controlled for. 
 
 
As can be seen in Table 3.10, there is no significant relationship between age and 
amygdala volume in either the study or control groups.  There is a tendency for a 
greater negative relationship between left amygdala volume and age in the study 














































































Use of parametric statistics 
 
  
 The use of parametric statistics is dependent on a number of assumptions 
being made about population distributions and parameters.  Namely, the populations 
are assumed to have normal distributions and equal variances.  Justification on the 
former count was provided by checking the standardised residual plots for normality 
and finding them satisfactory.  The requirement for comparable variance was more 
problematic.  When checked by Levenes test, this was a significant difference, and it 
is acknowledged that this can potentially result in a type 1 error.155  It is accepted 
however that when sample sizes are equal this does mitigate the effect of unequal 
variances and in these circumstances the use of parametric statistics can be 
justified.155  Given this, together with the fact that group sizes were reasonable, I felt 
that parametric statistics could be applied to this data set.  As there are theoretical 
concerns about criteria being satisfied however I also compared the means of the two 
groups using non-parametric methods.  The results employing parametric and non-
parametric methods were comparable.  
 
 
Covariation for IQ 
 
  
 On comparison of CBCL+/SIS+ and control raw data, it can be seen that 
amygdala size is greater in the latter, for both left and right amygdala in males and 
females.  When data for each sex are combined and gender covaried for this trend 
persists, though does not reach statistical significance.  When data is covaried for IQ 
as well as gender however, for the right amygdale at least, the difference is 
statistically significant.  On analysis, a significant group by IQ interaction is seen. 
This inevitably brings into question the appropriateness of covarying for IQ.  
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 In the design of the ESC, both normal and learning disabled controls were 
included.  Ideally of course, amydala volume in the study group would be compared 
to both controls.  Unfortunately however, determination of amygdala volume in the 
learning disabled control group was outwith the scope of this study. Covariation of the 
data for IQ could potentially allow more appropriate comparison of these clearly very 
different groups.  Covariance is often employed in matching designs to control for 
factors that have not been matched for.28  One disadvantage of this approach however 
is that it assumes certain statistical properties of the data (normalcy, variation); this 
issue is discussed above.  Additionally, the result of analysis of covariance are 
considerably less interpretable if the groups differ substantially on the covariate in 
question,28 a fact clearly relevant to this data.  It also requires that all subgroups 
within the data set show the same pattern of relationship between amygdala size and 
IQ, a fact that may be particularly questionable within the heterogeneous study group.  
Perhaps the strongest argument against covariation for IQ however comes from the 
premise for the study itself.  The rationale for the study rests on the assumption that 
low IQ may be a manifestation of undiagnosed schizophrenia.  Thus, if IQ is 
controlled for it is possible that structural abnormalities associated with this 




Covariation for whole brain volume 
 
  
 It is recognised that variation in the sizes of specific brain structures tends to 
be correlated with normal variation in brain size.  Thus, people with larger brains tend 
to have larger brain structures, lateral ventricles, grey matter, and so on.  A positive 
relationship has specifically been reported between head size and amygdala 
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volume.156  Thus, brain size can potentially introduce confounding variance or noise 
into quantitative brain data.  Accordingly, many researchers have tried to reduce the 
influence of brain size variation, producing structural data corrected for brain size.  
Various methods can be employed to do this.  The two most commonly used are 
either creation of a structure of interest to brain volume proportion or multivariate 
techniques such as analysis of covariance to covary data for whole brain volume.  It 
has been argued that the latter is more appropriate.157,158 
 Despite the above, it has also been argued that data should be presented in the 
most direct way, with raw volumes used.  Bogerts et al discuss that though sex 
differences do need to be controlled for, use of raw volumes is valid for within group 
comparisons.159  Though clearly a heterogeneous group, the analysis of association 
between score on PANSS and amygdala size within the high risk group could be 
regarded as such a situation. 
 It is certainly not universal practice to adjust data to take account of whole 
brain volume, and given the above arguments I have presented data in the raw form.  
On considering these arguments however, and particularly given that the study group 
is known to be heterogeneous, it seems most appropriate for analyses to take account 
of whole brain volume.  As it is generally believed that the most appropriate 





It needs also to be acknowledged that much data in this study has been subject 
to multiple comparisons. This does of course bring with it the risk of a type 1 error. 
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Though it is the case that the hypotheses being tested were planned, rather than post 
hoc, this fact must still be acknowledged. As such, findings are best regarded as 












































































5.1 Part 1  Introduction to discussion 
 
 Any comparison of the amygdala volumes observed in the SIS+/CBCL+ and 
control groups must be placed within the context of normal amygdala development 
during adolescence.  This is particularly important as it has been proposed that 
adolescence is a period associated with substantial neurobiological change, and more 
specifically that it involves a shift from greater limbic to prefrontal cortical control of 
behaviour.160  These neural changes are believed to underlie a shift from behaviour 
that is driven by affective impulses to more regulated behaviour that is guided by 
consideration of future personal and social consequences.161  As discussed in Section 
1.1, there is evidence to suggest that the amygdala has a role in emotional recognition 
and experience, motivated behaviour and social cognition; these are spheres that 
clearly have potential import in the processes undergoing development during 
adolescence.  Given these postulated roles, it is thus unsurprising that the amygdala 
has been suggested to be one of the brain regions to undergo change in the process of 
adolescent brain development.162    
 In light of the above it is surprising that there are in fact very few studies 
employing neuroimaging to investigate amygdala development during adolescence.  I 
was able to identify only one longitudinal study providing such data, the control group 
of the NIMH study of childhood onset schizophrenia.73  Thirty-six subjects from the 
control group had longitudinal scans.  They had a mean age of 13.6 (SD 2.6) at the 
time of the initial scan, and 16.2 (3.1) at the time of the second scan.  Statistical 
analysis employed methodology that combined cross-sectional and longitudinal data.  
From this analysis they concluded that in normally developing individuals amygdala 
volume does not change significantly within the age range investigated (13-18).73 
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 Though the NIMH study is the only I could identify incorporating longitudinal 
data, others have directly addressed the using cross-sectional techniques.  The largest 
of these, from the same group as the study above, involved 99 children aged 4-18 
years.  The left amygdala was found to increase significantly with age, but only in 
males.163  Schumann et als study of the amygdala in autism included 27 typically 
developing (all male) controls.128  In this case the controls were divided into two 
groups of subjects (one aged 7.5-12.5 years, the other 12.5-18.5 years); the volume of 
the amygdala in the older group was significantly greater than in the younger group.  
This was despite the older group having significantly smaller total cerebral volume.  
In contrast to these two findings are those from a cross-sectional study by Chen et al 
investigating amygdala development in adolescents with bipolar disorder and 
including 21 healthy controls (9 female and 12 male; age 11-21).164  In this study a 
significant inverse relationship was seen between age and volume of the left amygdala 
in males (and they alone).  It is the case that many of the subjects in the latter study 
will be post adolescence, but the range of ages included is comparable to the present 
study.   
 In summary, though there is a paucity of longitudinal studies, what evidence 
there is does suggest that, (for males at least), the process of transition from early to 
late childhood may involve an increase in amygdala volume.  In the period of later 
adolescence/early adulthood it is unlikely there is any increase in volume, and (for 
males at least), there may actually be a decrease.  It is this age range which is the 
focus of the present study.      
 An additional important additional consideration when investigating subtle 
differences in small, subcortical structures is that there is an inherent limit to the 
resolution of the imaging technique employed.  This further hampers the accurate 
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delineation of anatomical boundaries,79 and makes it particularly difficult to identify 
any structural changes that may be occurring when, for example, an individual 
undergoes the process of transition to schizophrenia.  In short, even if differences 
from controls are not detected, it does not mean they are not present.      
  
 
5.2 Part 2  Comparison of amygdala volume in the study and control groups 
 
Amygdala volume was not reduced in the SIS+/CBCL+ group  
 While acknowledging the limits inherent to the techniques employed, it had 
been expected that amygdala volume in the CBCL+/SIS+ group would be reduced 
compared to controls.  This expectation is based on four central findings, discussed in 
the introduction: 1) Amygdala volume is reduced in those with schizophrenia, 2) The 
volume of the AHC is reduced in those at high risk of schizophrenia, 3) Individuals 
comorbid for learning disability and schizophrenia have reduced volume of the AHC, 
4) Within a high risk population those who will develop schizophrenia can be 
identified by scores above cut offs on the CBCL and SIS.  This was not seen however.  
Indeed, after covariation for gender and IQ (the latter being a questionable practice, as 
discussed above), right amygdala volume was significantly greater in the study group 
than controls.  Even without covariation for IQ there is a definite bilateral trend 
towards larger amygdalae in the study group which approached significance.  There 





5.2.1 It is incorrect to expect reduced amygdala size in an adolescent population at 
elevated risk for schizophrenia. 
 
 Though there is substantial data that amygdala volume is reduced in 
established schizophrenia, the bulk of this data originates in adult populations.  Data 
concerning amygdala volume in younger populations, as discussed in Section 1.3, is 
more inconsistent on this matter.  The EHRS did of course involve an adolescent 
group but, as will be discussed later, in this study the amygdala and hippocampus 
were measured together.  One particular data set of note is that of Levitt et al, who in 
their study of children with schizophrenia (mean age 14.2, SD 3.8 years) found that 
amygdala volume was significantly larger in subjects with schizophrenia than 
controls.70  There are clearly major differences between the cohort in the current study 
and that in Levitt et al; not least they are older (mean age16.1, SD 1.9), and do not 
have schizophrenia.  Nonetheless, this finding would clearly fit with the finding of 
larger amygdalae in a population thought to be at elevated risk of schizophrenia.  
Levitt et al suggest a hypothesis to explain the larger amygdalae of initial sparing of 
medial temporal regions in childhood-onset schizophrenia, which may then be 
overcome by a degenerative process associated with illness progression.70  This may 
of course have relevance to the cohort investigated in this study.      
  
 
5.2.2 Heterogeneity of study group 
 
 It is possible that although there is indeed a population within the 
CBCL+/SIS+ group that is destined to develop schizophrenia, other populations are 
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also present.  One of these populations may be a normal learning disabled group.  It 
was shown by Sanderson et al that the normal learning disabled population has a 
larger left amygdalahippocampal complex than controls.104  Admittedly this was only 
after controlling for whole brain volume, raw mean amygdala volume being slightly 
smaller.  Even in the case of raw mean volumes however, the standard deviation in 
the learning disabled group was greater than controls, indicating a greater range of 
volumes.  Though findings are contradictory, some studies have also found an 
enlarged amygdala in subjects with autism.128  This is of relevance to this study, as 
some subjects with autism may have been selected into the study group by the use of 
the CBCL and SIS. This possibility is discussed in more detail in Section 5.6.  If it is 
the case that autistic and/or normal learning disabled subjects have been included in 
the study group, we would thus expect to see a wide range of amygdala volumes, 
individuals being present with amygdala both smaller and larger than those seen in the 
control group.  This is indeed the pattern seen.  
 An alternative cause of heterogeneity of amygdale size is also suggested by 
the work of Sanderson.165  In her study investigating correlations between historical 
variables and cerebral structure in subjects comorbid for learning disability and 
schizophrenia, she noted a significantly larger right AHC in those who had 
experienced obstetric complications compared to those who had not. Again this was 
relative to whole brain volume.  It is also conceivable that within the CBCL+/SIS+ 
group there are subjects whose clinical presentation is caused by a distinct aetiology 




5.2.3 The CBCL and SIS do not predict those at elevated risk for schizophrenia in a 
learning disabled population 
 
 Scores on the CBCL and SIS were shown to predict those who developed 
schizophrenia in a population at high genetic risk for the condition.97  It is conceivable 
this is not the case in a learning disabled population.  Thus, it may be that for these 
individuals their learning disability is not a prodromal state, and they are not destined 
to develop schizophrenia.  If this population do indeed represent a normal variant of 
learning disability, then as was shown for the normal learning disabled 
population,104 larger amygdala volume would be expected.  The fact is however, that 
for the SIS in particular, the nature of the symptoms bear such similarities to 
schizophrenia, that it seem unlikely a subgroup of the learning disabled population 
scoring highly on this measure could be regarded as a normal population.  Even if this 
group is not destined to develop schizophrenia, they clearly score highly on 
schizotypal symptoms; as reviewed in Section 1.8, though inconsistent, there are 
reports that schizotypy per se is associated with reduced amygdale volume.40   
The argument that the CBCL and SIS do not predict schizophrenia in a 
cognitively impaired population is further undermined by recent findings from the 
ESC.100  During the time scale of the study three cognitively impaired individuals 
from the high SIS group have gone on to develop schizophrenia, and a further six 
have symptoms highly suggestive of the condition.  This is substantially more than 
would be expected by chance alone, and it does thus seem that these relatively simple 
tools do indeed predict increased vulnerability to schizophrenia within this 
population.    
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5.2.4 It is volume differences in the hippocampus, not amygdala that were detected in 
the study of subjects comorbid for learning disability and schizophrenia . 
 
 As discussed in Section 1.9, AHC volume is reduced in those at high risk for 
schizophrenia, and in those comorbid for learning disability and schizophrenia.  Given 
the limitations of imaging techniques at the times of these studies, the amygdala and 
hippocampus could not be accurately separated, and so were measured together.  In 
this study the amygdala could be delineated and so was measured separately.  It is of 
course possible that AHC volume is indeed reduced in the CBCL+/SIS+ group 
compared to controls, but this difference is seen in the hippocampal rather than 
amygdalar component.  As only the amygdala is measured this would obviously go 
unnoticed.  
 It is indeed generally the case that in studies in which the amygdala and 
hippocampus are measured separately, the finding of reduced hippocampal volume in 
schizophrenia does seem more resilient.41  Indeed, Vita et al go so far as to suggest 
that of the two structures the hippocampus may be affected earlier in the course of the 
disease. Despite this however, a number of studies do indeed show substantially 
reduced amygdala volume relatively early in the course of the disease.34,51  
Reconciling these disparate findings will be difficult, but it is likely that this 
confusion reflects one of the major problems with structural imaging studies focusing 
on small structures such as the amygdala; namely, as discussed in the introduction, 
volume losses associated with conditions such as schizophrenia are at the limits of 
resolution of current imaging techniques.  Separation of the amygdala from the 
hippocampus results in an even smaller structure, compounding the problem, and 
making identification of volume differences in the study group even harder to detect.     
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   Considering all the data, it seems likely that both the amygdala and 
hippocampus are reduced in volume in schizophrenia both in learning disabled and 
non-learning disabled individuals.  Whether there are any abnormalities of amygdala 
volume prior to disease onset is much more difficult to clarify.   
 
 
5.2.5 At risk have larger amygdalae premorbidly, but this reduces at disease onset.  
 
 Related to the above point is the possibility that though amygdala volume is 
reduced in established cases of schizophrenia, this is not the case before the individual 
has developed psychosis.  In short, amygdala size reduces at the time of illness onset, 
possibly reflecting a process associated with disease onset that occurs at this point in 
schizophrenia aetiology.  It may even be that prior to the point of volume reduction, 
an increase in amygdala volume is seen, reflecting increased activity in this structure, 
or a protective response to prevent decline into psychosis.  Indeed, this could 
potentially fit with psychopathology experienced at this time.  Further findings from 
the EHRS are that anxiety symptoms are a prominent feature in the prodromal period 
prior to illness development, and that they may diminish with onset of psychosis.166  
Though obviously non-specific, it was identified as one of the earliest features 
predictive of schizophrenia.  Other investigators have commented on anxiety being 
pathologically absent in the chronic stages of schizophrenia,161 though it has been 
argued that experience of such emotions continues, despite expression being markedly 
reduced.25  Given the purported involvement of the amygdala in the emotions of fear 
and anxiety,4 it is intriguing to speculate that this prodromal anxiety may coincide 
with an increase in amygdala size prior to size reduction occurring with onset of 
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psychosis.  If this was the case, then an association may be expected between anxiety 
symptoms and amygdala size.  Though there is no evidence of this from the data, it 
may be of course that the group is too small or heterogeneous to reveal such a trend. 
Though data is sparse, there are studies that have reported an association between 
larger amygdala volume and anxiety symptoms.168 
 The idea that volume reductions in the AHC occur at the point of transition 
into schizophrenia does have some support from imaging studies from the Edinburgh 
High Risk Study. 56,58  It must be noted however that this study clearly identified 
reduced volume of the AHC before subjects had developed a formal psychotic illness, 
rather than structures being larger than controls, as seen in this study.  The fact that 
the amygdala and hippocampus were measured as a single entity and that this may 
obscure differences of amygdala size in high risk subjects and controls at every time 
point must of course again be emphasised. 
 
 
5.2.6 The CBCL selects a group with enlarged amygdalae 
  
 As discussed above, at the outset of this study it was expected that amygdala 
volume would be reduced in the CBCL+/SIS+ group compared to controls.  This was 
not found however, amygdala volume actually being larger in the CBCL+/SIS+ 
group.  Indeed, when raw data for the right amygdala were compared this fell just 
short of significance, and when this comparison was repeated with covariation for IQ, 
(along with gender and whole brain volume), it actually reached significance.  As 
discussed in Chapter 4, covariation for IQ is probably not appropriate for this study, 
but nevertheless these findings are striking and require further discussion. 
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 One possible explanation for this unexpected finding comes from studies 
investigating amygdala abnormalities in children with behavioural disturbance.  Of 
particular note in relation to this is work of Whittle et al investigating brain structural 
correlates with adolescent affective behaviour.162  As part of a broader study, they 
measured amygdala volume in a sample of 137 adolescents without a diagnosis of 
mental illness or learning disability.  The relationship between amygdala volume and 
measures of various behaviours assessed during parent-child interactions was then 
ascertained.  As predicted by the baseline hypothesis, the duration of aggressive 
behaviours during a conflict resolution interaction with parents was predicted by the 
volume of the amygdalae; the association with the left amygdala was significant (P = 
<0.05), while the association with the right amygdala fell just short of significance (P 
= 0.057).   
 As discussed in the introduction, the study group in this report were selected 
from a population with special educational needs on the basis of scores on the CBCL 
and SIS.  The CBCL is a tool, generally rated by parents, with which children are 
rated on the levels of various problem behaviours exhibited.  These constitute eight 
constructs or syndromes, two of which are delinquent behaviour and aggressive 
behaviour.  For entry into the study group the cut off chosen was 86, which 
(unsurprisingly given the nature of the population), is higher than the cut off used for 
caseness in other studies.169  Given the nature of many of the problems identified by 
the CBCL, it would be expected that individuals scoring highly on it would also 
exhibit longer duration of aggressive behaviour during conflict resolutions.  In short, 
groups identified by score on the CBCL and aggressive behaviour during interactions 
with parents may share some characteristics.  If this was the case, then on the basis of 
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the work of Whittle et al there would be a significant association between score on the 
CBCL and amygdala volume (being particularly the case for left amygdala).    
 As was seen in Table 3.8, within the CBCL+/SIS+ group the association that 
may have been expected between score on CBCL and amygdala volume was not seen.  
Within the control group however the picture is rather different.  After controlling for 
gender and whole brain volume, a significant positive association is seen between 
score on CBCL and volume of the left amygdala (P = 0.049), with this being even 
more significant on controlling for gender alone (P = 0.035).  Additionally, when the 
two groups (CBCL+/SIS+ and controls) are combined and the analysis repeated for 
all subjects (again controlling for gender and whole brain volume), a significant 
association is again seen between score on the CBCL and volume of the left amygdala 
(P = 0.035). 
 From the discussion above it can be seen that there is an association between 
score on the CBCL and increased amygdala volume, this being statistically significant 
on the left side.  This is compatible with the data reported by Whittle et al,162 and 
would provide an explanation as to why, in contrast to what had been expected at the 
outset of the study, amygdala volume was increased in the CBCL+/SIS+ group 
compared to controls.  What is not seen however is an association between score on 
the CBCL and amygdala volume within the study group.  On reflection however, I do 
not feel that this is particularly surprising.  Firstly, it is the case that all subjects within 
this group are scoring highly on this rating scale, thus reducing the spread of scores 
and reducing the likelihood of a significant finding.  Secondly, as discussed above, 
this is a very heterogeneous group; there are likely numerous influences on amygdala 
volume, again making a significant association between score on CBCL and 
amygdala volume unlikely.     
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5.2 Part 2 - Relationship between score on PANSS and amygdala volume 
 
 A significant association was seen between score on the negative symptom 
category of PANSS and reduced left amygdala size within the study group.  This 
persisted after adjustment for whole brain volume. One possible explanation for it is 
that individuals undergoing the process of transition to schizophrenia experience a 
reduction in amygdala volume, this occurring before they fulfil diagnostic criteria for 
the illness.  This process may be manifest clinically as the development of negative 
symptoms.  Indeed, the concept of the schizophrenic prodrome has long been 
recognised, encapsulating the period when an individual destined to develop 
schizophrenia becomes more withdrawn and introverted and loses drive, 
determination and interest.170  These are clearly negative-type symptoms. 
 The idea that the period preceding transition to frank psychosis may be 
associated with structural brain changes is not new.  As discussed in section 1.2.5, 
Lawrie et al observed reductions in temporal lobe volume (statistically significant on 
the right side) in a longitudinal study comparing those who developed transient 
psychotic symptoms to those who didnt within a high risk population.58  The 
Melbourne group have also reported longitudinal temporal lobe grey matter changes, 
in the case of their study over the period of transition from prodrome to frank 
psychosis.55  
 An alternative explanation for the association of greater weight of negative 
symptoms with smaller amygdala is that the association is static in time, i.e. there is a  
subgroup within the CBCL+/SIS+ cohort with a longstanding co-occurrence of 
smaller amygdala and more negative symptoms.  This is supported by the absence of 
a significant association between age and amygdala volume in the study group.  Given 
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that the data are from a single time-point however, it is impossible to be certain if this 
is a trait or state association.  The possibility and implications of this association 
being a trait or state characteristic will be discussed further below. 
 Smaller amygdala were associated with greater weight of negative symptoms 
on both the right and left sides. This association was much more marked on the left 
however, and was only statistically significant on this side. Considered with the 
findings from studies of amygdala volume in established schizophrenia this is itself an 
interesting finding.  As noted in section 1.6, in studies in which smaller amygdala are 
seen only unilaterally, this is almost invariably on the left side.  Studies with unilateral 
findings tend to be first episode studies, which may suggest that left amygdala volume 
loss occurs earlier in the course of schizophrenia than right.  If this was indeed the 
case, then this would fit with the findings of this study.  If the subjects within the 
study group with a higher weight of negative symptoms were indeed beginning the 
process of transition to schizophrenia, they would be expected to exhibit the structural 
correlates of this; they would be expected to have smaller left amygdala.  
 Findings relevant to the discussion of laterality of amygdala volume loss are 
also apparent from the studies of Sanderson et al and Moorehead et al of 
schizophrenia in learning disability.104,114  In the VBM analysis of this data, smaller 
amygdala in comorbids compared to controls was seen only on the left side.114  It is 
interesting that once again in this study it is the left side which shows the strongest 
association between volume reduction and greater weight of negative symptoms.  This 
would be compatible with a model of schizophrenia in which the left amygdala rather 




5.3 Part 3 - Relationship between age and amygdala volume in the study and 
control groups. 
 
 The relationship between age and amygdala volume was determined in both 
the study and control groups.  In both groups there was a non-significant, negative 
relationship between increasing age and left amygdala volume.  This relationship was 
slightly stronger in the study group compared to controls, but the difference in the 
relationship between the two groups still fell far short of significance.   
 The relationship between amygdala volume and age seen in the control group 
is compatible with the existing data addressing amygdala volume changes with age 
during the period of adolescence/early adulthood.  This data was discussed in Section 
5.1.  In contrast, the lack of a significant association between amygdala volume and 
age within the study group is more surprising.  As discussed above, it is being 
suggested that the association between reduced amygdala volume and greater weight 
of negative symptoms represents the beginning of a process of transition to 
schizophrenia; if this is the case however then older subjects within the study group 
would be expected to have advanced further along this course and thus have smaller 
amygdalae.  A significant negative association between age and amygdala volume 
would thus be seen; this is not the case.  Potential explanations for the absence of this 






5.4 Part 4 - Reconciling the relationship between score on PANSS and age within 
the study group and absence of a significant trend towards greater amygdala 
volume loss with age in this group.  
 
 A significant association was seen between score on both the negative and 
disorganisation symptom categories of PANSS and age within the study group, i.e. 
the older an individual within this particular high risk group is, the greater the chance 
they will exhibit disorganisation and negative symptoms.  As an isolated finding this 
would not support a static explanation for the association between greater negative 
symptoms and smaller amygdala size, but would be consistent with the hypothesis 
that there is a process occurring within the study group that is resulting in them 
accruing negative symptoms and losing amygdala volume. 
The above finding must be considered together with data comparing the 
relationship between amygdala volume and age in the study and control groups.  As 
described above, in both groups there was a non-significant, negative relationship 
between increasing age and left amygdala volume.  This relationship was not 
significantly greater in the study group than the control group.  Given the relationship 
between age and negative symptoms, this result is somewhat surprising.  If it is 
postulated that a process of transition to schizophrenia is occurring in the study group, 
and this is manifest as a loss of volume and accumulation of negative symptoms, then 
it would be expected that there would be a more marked association between 
increasing age and smaller amygdala volume in the high risk group.  Clearly, this is 
not seen.    
 A number of possible explanations can be proposed to explain the absence of 
this association. These are outlined below: 
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5.4.1 Anomalous nature of control data 
 
 This explanation is unlikely.  As discussed above the association between 
amygdala volume and age within the control group is compatible with existing data.73 
 
 
5.4.2 Lack of statistical power 
 
 A definite trend was seen towards increasing age being associated with 
reduced volume of the left amygdala, the P value being 0.106.  It is conceivable that 
had the study group been larger, this would reach significance.  
 
 
5.4.3 Heterogeneity within study group  
 
 An alternative explanation could stem from the heterogeneous nature of the 
CBCL+/SIS+ group.  It could be argued that though an association between 
increasing age and smaller amygdala volume does exist within a subset of the group, 
it is being masked by another subset in which there is a different relationship between 







5.4.4 Dynamic processes occurring in amygdalae of study group 
 
 If the period preceding development of schizophrenia was characterised first 
by enlargement of the amygdala and then volume loss, then it would be unlikely that 
overall a relationship between age and loss of volume would be seen.  If a period of 
anxiety associated with increased amygdala volume was followed by volume loss 
associated with negative symptoms, then it can be seen how this lack of an association 
between smaller volume and age could co-exist with an association between greater 
weight of negative symptoms and increasing age.  There is indeed some data 




5.4.5 The association between smaller left amygdala and greater weight of negative 
symptoms is a trait characteristic 
 
 Despite the discussion above, it must also be acknowledged that absence of a 
significant difference in the rate of volume loss with age in the study group compared 
to controls may best fit with a static explanation for the association between more 
negative-type symptoms and smaller amygdala.  This would suggest that within a 
group of learning disabled subjects shown by other measures to be at high risk for 
schizophrenia there is a subgroup who display both relatively smaller amygdalae and 
a greater weight of negative symptoms, this being a trait association.  Given that the 
basic premise for this study was that there may be a subgroup of learning disabled 
individuals whose cognitive impairment is due to a schizophrenic illness yet to 
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become manifest as psychotic symptoms, this is an intriguing possibility.  It may be 
that within this group those individuals with relatively smaller amygdalae and more 
negative symptoms are at even greater risk of developing schizophrenia than the 
group as a whole.  As and if illness develops it would be expected that there would be 
further volume reduction at that time point, associated with worsening of negative 
symptomatology and emergence of frank psychotic symptoms.  Clearly follow up will 
be required to determine if these characteristics truly do identify an ultra-high risk 
group.  If this is the case however, then it may be that these are further characteristics 
which can be used to refine models designed to predict the risk of schizophrenia 
developing in a learning disabled individual.       
  
 
5.4.6 Increase in weight of negative symptoms with age is due to a process in which 
the amygdala is not of primary importance. 
 
 It is clear that within the study group there is a strong association between 
smaller left amygdala volume and greater weight of negative symptoms.  It is also 
clear that the strength of this association increases after covariation for age.  Thus, it 
is not simply that age is a confounding factor.  It is also the case however that given 
that amygdala volume does not seem to decline significantly with age in the study 
group, loss of amygdala volume in a pre-schizophrenic population is unlikely a 
continuous, progressive process.  Thus, while a baseline increase in negative 
symptoms may well be related to amygdala volume loss, as time progresses changes 
in other parts of the brain may be more important in worsening of this 
sympomatology. 
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 On considering the above, it can be seen that there is commonality with the 
two-hit hypothesis of schizophrenia.  One interpretation of this model, as proposed by 
Karachi, is that temporal lobe changes may underlie a vulnerability to schizophrenia, 
with latent dysfunction in these regions becoming clinically apparent as positive 
symptoms due to additional frontal lobe changes.171  The inter-relationship of these 
two brain regions and its potential importance in schizophrenia is also discussed.  Of 
particular note they cite data providing evidence of a significant relationship between 
the volume of the prefrontal lobe and the volume of temporal lobe structures in 
patients with schizophrenia, this not being present in healthy controls. 171  This would 
support the hypothesis of a dynamic interaction between these two brain regions being 
important in the aetiology of schizophrenia.     
Interpreting this model in light of my data, it is conceivable that relatively 
smaller amygdalae in individuals at high risk for schizophrenia reflect structural 
abnormalities of the region.  Within a pre-illness group such as this, these 
abnormalities may give rise to a degree of negative symptomatology.  As further 
changes occur however, possibly as a consequence of additional frontal lobe changes, 
frank psychotic symptoms will emerge, negative symptomatology worsen and a 










5.5 Part 5 - Relationship between amygdala volume and score on positive 
symptom subset of PANSS 
 
 No association was seen between size of either left or right amygdala and the 
positive symptom subset of PANSS.  A number of explanations can be proposed for 
this finding.  One possibility, as alluded to above, is that while negative symptoms 
arise from amygdala abnormalities, other structures are more important in positive 
symptoms.  Alternatively, it may be that early and possibly longstanding changes in 
amygdala structure are important in negative symptoms, while later changes, reflected 
in further volume loss, are more important in positive symptoms.  This does not deny 
the importance of the amygdala in these later symptoms; it simply means that as 
individuals in this population who are destined to develop schizophrenia are early in 
this process, the changes associated with positive symptoms would not be expected 
yet.  Alternatively, it may be that amygdala changes are indeed important in the 
manifestation of schizophrenia, and this process has occurred, but another part of the 
brain is compensating for abnormalities of amygdala function at this timepoint.  As 
the compensating structures become less able to perform this function, positive 
symptoms of schizophrenia may develop.  This would fit with data from the 
Pittsburgh high risk study which was discussed earlier; though AHC volume 
reductions were seen in this population, reductions of the dorso-lateral prefrontal 






5.6 Part 6 - Relevance of autism data to the relationship between amygdala size 
and score on the negative symptom subset of PANSS 
 
 There is a further body of research relevant to discussion of the relationship 
between amygdala volume and score on the negative symptom subset of PANSS.  
This is research investigating amygdala volume in autism.  
 It is well recognised that there are similarities between the autistic spectrum 
disorders and schizophrenia, and that this is particularly the case for the negative 
symptom subset of the latter condition.  Indeed, the extent to which these clinical 
presentations may overlap has been formally researched.  In a study of 21 individuals 
with chronic, treatment resistant schizophrenia Sheitman et al found that autistic 
features as measured by the Autism Behaviour Checklist correlated with the degree of 
negative but not positive symptoms.172  Examining the issue from the opposite 
direction Konstantareas et al found that 50% of autistic individuals met diagnostic 
criteria for schizophrenia, disorganised type with negative symptoms.173  In a direct 
comparison of autism and schizophrenia the autistic subjects were found to have 
significantly less positive thought disorder than schizophrenic subjects but with no 
difference in measures of affective flattening.174  These findings indicate that negative 
symptoms are shared between the disorders but that autistic individuals do not show 
the same degree of positive symptomatology as is found in schizophrenia.  There are 
two possibilities which could explain this commonality; either negative symptoms of 
schizophrenia and autistic features are different phenomena which are simply difficult 
to distinguish clinically, or they represent the same underlying pathophysiogical 
process.  If the first possibility is true, then it is indeed possible that some subjects on 
the autistic spectrum were included within the CBCL+/SIS+ group.  
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  It has been reported that, compared to controls, the amygdala is enlarged in 
children but not adolescents with autism.128  Indeed, in autistic adults it may even be 
smaller than that of control subjects.175,176  It thus seems likely that though in younger 
children the amygdala is larger in autistic than normally developing subjects, in older 
children there is little difference in size.  Thus, given that the CBCL+/SIS+ cohort is 
an adolescent group, if there were autistic individuals in it, these individuals would 
tend to have similar size amygdalae to control subjects.  The very youngest may be 
expected to have marginally larger amygdalae, and the oldest marginally smaller.  In 
the group as a whole however, it would be expected that there would be no significant 
difference between amygdala volumes.  This is of course what is seen.  As autistic 
symptoms would not be expected to increase with age, the association between 
increasing age and greater weight of negative symptoms would not be expected if 
these symptoms were indeed due to autism.  This argues against autistic traits 




5.7 Part 7 - Integration of findings into broader knowledge base of aetiology of 
schizophrenia 
 
 There are two core findings from this study.  The first is that, contrary to what 
may have been expected, when compared to controls there was no evidence for 
reduced amygdala volume in a learning disabled population with no history of 
psychosis, but at high risk for developing schizophrenia.  Indeed, though it fell just 
short of statistical significant, mean amygdala volume was actually larger than in the 
control population.  The second is that within the population at high risk for 
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schizophrenia, greater weight of negative symptoms was associated with smaller 
amygdala volume; this association was statistically significant.  The question of 
whether this is a trait characteristic or represents the beginning of a process of 
transition to schizophrenia cannot be adequately answered on the basis of this cross-
sectional study.  If it is the case that further study of this group reveals further loss of 
amygdala volume and this correlates with a further increase in weight of negative 
symptoms then it would of course favour the latter.  Regardless of what happens in 
the future however, it is the case that this association exists at present.  Given this it is 
important to appreciate how these two findings integrate with other published findings 
from the comorbidity study, the broader knowledge base for the aetiology of 
schizophrenia and what is known about the role of the amygdala in mental and 
behavioural disorders in general. 
 
 
5.7.1 Integration of current findings with previous publications from this study group  
 
 The principle publications of relevance to this report that have arisen from the 
comorbidity study are those of Spencer et al. Spencers 2007 paper discussed grey 
matter correlates of early psychotic symptoms in adolescents at elevated risk of 
psychosis.177  It is important to underline that the group under investigation in this 
study was selected on the basis of receiving additional learning support; they had not 
been selected for enhanced vulnerability to schizophrenia on the basis of the SIS and 
CBCL.  Thus though they did have the three fold elevation of risk conferred by being 
learning disabled, they would be expected to be at significantly less mean risk than 
the population in this study.  Findings included a significant negative correlation 
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between anxiety and grey matter density of the left hippocampus. No significant 
associations between specific symptoms and amygdalar density are reported.     
 
 
5.7.2 Integration of current findings with the broader knowledge base for aetiology of 
schizophrenia 
 
 It is clear that cognitive dysfunction is a cardinal feature of schizophrenia, and 
the condition is widely regarded as a neurocognitive disorder.  As discussed in the 
introduction however, there has also been substantial interest in the importance of 
emotional brain systems in the disorder, which may transpire to be as important.  As 
the amygdala is viewed to be central to emotional experience, learning and 
memory,25,178 it is thus unsurprising that significant attention has focussed on this 
structure.  It is important that an attempt is made to integrate the findings discussed 
above into a model addressing the neurobiology of emotional processing in 
schizophrenia. 
 In their review, Alemann and Kahn attempt to explain the emotional 
abnormalities characteristic of schizophrenia by proposing a model in which (1) a 
dopamine imbalance underlies the increased emotional experience associated with 
psychosis, whereas (2) structural volume reductions of the amygdala and reduced 
connectivity with the prefrontal cortex underlie the emotion perception deficit and the 
reduction in emotional expressive behaviour.25  Elevated levels of dopamine would be 
important in the former, whereas structural lesions of the amygdala would give rise to 
the latter.  They stress that the focus on a lesion in the amygdala can explain the 
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emotion paradox of schizophrenia, whereby deficient recognition of emotion 
expressions and social perception coexists with largely intact emotional experience.  
 When discussing neural mechanisms underlying the negative symptoms of 
schizophrenia, Alemann and Kahn refer to the model proposed by Grossberg.179  The 
essence of this model is that emotional centres of the brain, in particular the 
amygdala, interact with sensory and prefrontal cortices to generate affective states and 
elicit motivated behaviours.  If emotional centres become depressed, feedback loops 
are disturbed and negative symptoms emerge.  Thus, a primary lesion in the amygdala 
can have widespread effects.  Specifically, it is suggested that one possible cause of 
decreased prefrontal activity in schizophrenia may be a reduction in incentive 
motivating signals from depressed amygdala circuits that project to the prefrontal 
cortex.  
  Though Grossbergs model can go some way to explain the occurrence of 
negative symptoms in schizophrenia, it does not account for positive symptoms; these 
are, of course, generally the most striking manifestations of the illness.  A model 
which can potentially account for the genesis of these symptoms, the process of 
aberrant assignment of salience to otherwise insignificant stimuli, was discussed in 
Section 1.1.25,180  It is important to recap and expand on this model at this point.
 Kapurs model was built on theories of the role of mesolimbic dopamine in the 
healthy brain.181  In this context it is argued that mesolimbic dopamine acts to provide 
significance or salience, transforming an affectively neutral stimulus into an attractive 
or aversive one.182  Thus, mesolimbic dopamine activity may determine whether an 
intrusion into awareness from either external perceptual or internal mental sources 
receives a positive or negative hedonic vector and thus grabs the attention of the 
individual.  If psychosis were associated with increased, stimulus-independent, release 
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of dopamine, salience would be granted to what would otherwise be relatively 
innocuous events or stimuli.181  This process has been succinctly described as 
dopamine providing the wind to the psychotic fire.183 
 Such a theory of aberrant assignment of salience integrates well with a 
model of emotional hyperarousal advanced by Grace.  In this model the amygdala is 
assumed to play an important role in a circuit including prefrontal pathways to the 
nucleus accumbens.25  The nucleus accumbens is a structure considered central to 
motivated behaviour, drive and salience184 and is widely regarded to be an important 
site for antipsychotic drug action.25  Within this model, according to Grace, the 
prefrontal cortex provides multiple motor plans by which it drives goal-directed 
behaviour.185  The most effective plan is then selected within the nucleus accumbens 
via the facilitatory effects of hippocampal and amygdalar infuences.  In normal health 
interplay between the hippocampus and the amygdala helps to maintain an individual 
in emotional balance.  The hippocampus, with input from the prefrontal cortex, sets 
environmental stimuli in the context of the current situation or past experience of the 
stimulus, and only response patterns that are appropriate to a given context are 
allowed to impact on mesolimbic dopamine.  In the case of a high affect value 
stimulus (e.g. implying threat to the organism), the amygdala can over-ride the 
hippocampal influence to direct behaviour in order to immediately and effectively 
deal with the challenge.  In schizophrenia, according to the model, due to an 
imbalance in dopamine systems, the amygdala becomes hyperactive and not only fails 
to facilitate prefrontal cortical throughput, but actually competes with it for driving 
nucleus accumbens activity.  The system thus responds inappropriately to otherwise 
insignificant stimuli (which acquire salience), leading ultimately to paranoia and 
psychosis.25,181   
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 In the models outlined above, it is being suggested that abnormalities of 
amygdala function can account for both the positive and negative symptoms of 
schizophrenia.  In the case of positive symptoms this involves overactivity, while 
negative symptoms are due to underactivity.  Such a model may superficially seem to 
lack coherence, but conceptualisation of the amygdala as a heterogeneous, 
multifunctional structure can reconcile this apparent contradiction.  This issue is 
further addressed in the review of Aleman et al.      
 Central to the hypothesis that amygdalar abnormalities can account for both 
constellations of symptoms is evidence concerning the function of two particular 
regions of the amygdala.  These two regions are the basolateral nucleus (BLA) and 
central nucleus (CeA).  The former is believed to play a role in forming associations 
between sensor stimuli and biologically significant events that have emotional and 
motivational valence.184  Output from this region flows to motor circuits of the 
striatum and cortex (allowing active responding to emotionally arousing stimuli), but 
also to the CeA.  The CeA activates brain stem areas involved in controlling specific 
involuntary components of emotional reaction, e.g. autonomic and endocrine 
responses.25  Building on this model, it is proposed that in schizophrenia there may be 
a lesion to the BLA, which would cause deficiencies in processing emotional stimuli 
and emotional learning; the existence of such deficits were discussed in Section 1.1.  
Additionally this deficit, likely combined with reduced prefrontal connectivity, would 
also lead to a reduction in active emotional responses, manifesting as negative-type 
symptoms such as emotional flattening and withdrawal.  It is also proposed that such 
a lesion could have consequences for the input to the CeA.  Reduced prefrontal 
control of the BLA may lead to aberrant activity of the CeA, autonomic arousal and 
subjective anxiety.25   
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 The above model also dovetails neatly with the hypothesis of aberrant 
assignment of salience being central to the genesis of positive symptoms.  It has been 
suggested by Philips et al that the CeA and BLA exert different influences on the 
mesocorticolimbic dopamine system.184  Within this model, the CeA maintains 
control of tonic activity of ventral tegmental dopamine neurones serving the nucleus 
accumbens and prefrontal cortex.  If inhibitory control of the CeA is reduced, then 
this would result in increased tonic dopamine levels within this system.  This would 
then result in the assignment of emotional salience to otherwise insignificant stimuli.25 
On considering the models outlined above, the relevance of findings from this 
study are potentially significant.  From the above it would be expected that if an 
individual experienced a reduction in incentive motivating signals to the prefrontal 
cortex, these would be clinically manifest as negative type symptoms.  As discussed 
in section 5.2, negative-type symptoms can precede diagnosis of schizophrenia by a 
substantial period of time, and could be present in the absence of frank psychosis. 
Thus, in a population at elevated risk of schizophrenia but not yet psychotic, a greater 
weight of negative symptoms could reflect greater impairment of incentive motivating 
symptoms from the amygdala.  As described by Aleman, this impairment of amygdala 
function would be expected to have been initiated by a lesion to the structure, 
particularly the BLA.25  Given this, it seems logical to expect that the greater the 
extent of the lesion to the amygdala, the greater the impairment of this function, and 
thus the greater the weight of negative symptoms.  Ideally volume changes in 
particular regions of the amygdala would be evaluated separately, but unfortunately 
this is beyond the resolution of current imaging techniques.  Thus, only gross 
amygdala volume can be determined, but from the above this would be expected to 
 117
have an inverse relationship with the weight of negative symptoms experienced.  In 











































































Protocol for amygdala measurement 
 
 
 Protocol was based on that of Schumann et al.128  However given that the 
neuroanatomy of many of the special needs group differed markedly from that of the 
typical brain, this was modified slightly to further minimise reliance on landmarks 
external to the amygdale.  This is necessary to minimise the possibility of systematic 
error being introduced.  It was clear from a pilot study employing a provisional 
protocol that if fixed landmarks were used, even if they surrounded the amygdala, 
then there would be times when one would be including what was clearly empty space 
in the delineation of the amygdale.  For this reason a rule of being generally 
conservative, and only tracing what was clearly present was employed, rather than 
extending the amygdala tracing to where it would generally be bounded by a 
landmark.  This principle of tracing conservatively was also employed in other 
circumstances, such as when boundaries with white matter were indistinct. 
 
 
General tracing considerations 
  
 Tracing is carried out initially in the coronal view.  However some borders are 
much more easily seen in the sagittal view, and sometimes the axial view.  The 
sagittal view is particularly useful in the establishment of the posterior and anterior 
borders.  Superior and inferior should be examined on coronal and sagittal. 
All tracing was undertaken with frequent reference to an atlas of neuroanatomy to 




General points about tracing protocol 
 
 As mentioned above, tracing begins in coronal view, progressing through 
slices caudally to rostrally.  The amygdala emerges superolaterally to hippocampus.  
It appears on the same slice as the hippocampus for approximately 3-5 slices, moving 
inferomedially to encompass the hippocampal head on three sides- medial, lateral and 
superior.  It becomes indistinct in anterior slices; this means that the anterior border 
requires to be established almost entirely in the saggital view.  
 To further increase consistency between scans the contrast setting of 20/130 
was used for all tracing.  This setting could be adjusted to aid viewing of structures, 




 Appears superolateral to the hippocampus. Begin tracing here, though it will 
be edited in sagittal view.  The borders are: 
Superior: putamen and optic tract 
Inferior: temporal horn of lateral ventrical, or hippocampus or alveus 





Amygdala moves to encompass and then replace the hippocampus.  The borders are: 
Superior: laterally the putamen, medially the medial surface of brain 
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Medial: medial surface of brain 
Inferior: temporal horn of lateral ventricle, or hippocampus or alveus 
Lateral: white matter of temporal stem. 
 
In these slices the principle of conservative tracing is particulary crucial.  The lateral 
and medio-lateral borders are particularly indistinct, as the point where white matter 
begins is frequently not clear.  To avoid inclusion of the ventral claustrum in 
particular, caution was paid not to extend the outline of the amygdala into the 
temporal stem.  
 
 
Then, on reaching the more rostral portion of the amygdala the borders are: 
 
Superior: medial surface of brain 
Medial: medial surface of brain 
Infeior and inferomedial: white matter of entorhinal cortex. In practice, this white 
matter does not extend all the way to the medial surface however, and needs to be 
extrapolated.  If the semiannular sulcus is visible on the medial surface, then this line 
is drawn from the most medial point of the enterorhinal white matter to it.  If the 
semiannular sulcus is not seen, then a line of best fit is drawn.  Interpolation between 
slices may assist with this.  This is an area which can be considerably revised in the 
sagittal view, as the white matter white matter of the entorhinal cortex is frequently 
more visible in it.  
Lateral: white matter of temporal stem; again this can be indistinct, and a general rule 
of conservative tracing is followed. 
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Most rostral portion of the amygdala 
 
At this point the boundaries between grey and white matter become even more 
difficult to delineate.  At the most rostral point of the amygdala this becomes 
impossible, necessitating confirmation of the rostral boundary of the amygdala by 
review of sagittal images. 
 
 
Revision in sagittal view 
 
Scroll from lateral to medial.  Particular areas are consistently likely to need revision. 
 
1) Posterior border with the hippocampus.  
This is generally easily seen in the sagittal view.  There is a thin strip of grey matter 
which protrudes posteriorly from the superior edge of the amygdala; this is the 
hippocampal-amygdala transitional are (HATA), defined by Convit et al.153  It is 
edited out. 
 
2) Anterior border 
Difficult to see in any view.  The white matter separating amygdala from entorhinal 
cortex is frequently more visible in the sagittal view.  
 
3) Superior border 
White matter and optic tract act as borders.  This can assist with separation from the 
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